

Curriculum Vitae

Personal information

Surname(s) / First name(s) **Casali, Paolo Giovanni**
Address(es) Istituto Nazionale Tumori, via G. Venezian 1, 20133, Milano, Italy
Telephone(s) +39 02 2390 2184
Fax(es) +39 02 2390 2804
E-mail paolo.casali@istitutotumori.mi.it
Nationality Italian
Date of birth 28 December 1958
Gender Male

Work experience

Dates	From 1 November 2016 to present
Occupation or position held	Director, Medical Oncology Unit 2
Main activities and responsibilities	Chairing a medical oncology unit devoted to adult patients with sarcoma and coordination of the Italian Rare Cancer Network
Name and address of employer	Fondaz. IRCCS "Istituto Nazionale dei Tumori" , via G. Venezian 1, 20133 Milano , Italy
Type of business or sector	Medical oncology
Dates	From 1 November 2016 to present
Occupation or position held	Associate Professor of Medical Oncology
Main activities and responsibilities	Education and Research, Medical School
Name and address of employer	University of Milano , Italy
Type of business or sector	University
Dates	From December 2014 to October 2016
Occupation or position held	Director (ad interim), Medical Oncology Unit 2
Main activities and responsibilities	Chairing a new medical oncology unit devoted to adult patients with sarcoma and coordination of the Italian Rare Cancer Network
Name and address of employer	Fondaz. IRCCS "Istituto Nazionale dei Tumori", via G. Venezian 1, 20133 Milano, Italy
Type of business or sector	Medical oncology
Dates	From June 2011 to November 2014
Occupation or position held	Head, Adult Mesenchymal Tumour Medical Oncology Unit
Main activities and responsibilities	Coordinating a departmental medical oncology unit devoted to adult patients with sarcoma
Name and address of employer	Fondaz. IRCCS "Istituto Nazionale dei Tumori", via G. Venezian 1, 20133 Milano, Italy
Type of business or sector	Medical oncology
Dates	From April 2004 to May 2011
Occupation or position held	Head, Adult Sarcoma Medical Treatment Unit
Main activities and responsibilities	Coordinating a medical oncology unit devoted to adult patients with sarcoma

Name and address of employer	Fondaz. IRCCS "Istituto Nazionale dei Tumori", via G. Venezian 1, 20133 Milano, Italy
Type of business or sector	Medical oncology
Dates	From March 1994 to March 2004
Occupation or position held	Assistant physician
Main activities and responsibilities	Full staff position as Medical oncologist (with functional responsibility for adult sarcoma medical oncology from January 2002)
Name and address of employer	Istituto Nazionale Tumori, via G. Venezian 1, 20133 Milano, Italy
Type of business or sector	Health care: medical oncology
Dates	From October 1985 to February 1994
Occupation or position held	Clinical fellow / Associate Physician
Main activities and responsibilities	Non full staff positions as Medical oncologist
Name and address of employer	Istituto Nazionale Tumori, via G. Venezian 1, 20133 Milano, Italy
Type of business or sector	Health care: medical oncology
Dates	From 2003 to 2016
Occupation or position held	Adjunct Professor
Main activities and responsibilities	Teaching Medical oncology of rare cancers to postgraduate students of Oncology
Name and address of employer	Postgraduate School of Medical Oncology, Medical School, University, Milan, Italy
Type of business or sector	University
Dates	From 1999 to 2003
Occupation or position held	Tutor
Main activities and responsibilities	Tutoring postgraduate students of Oncology
Name and address of employer	Postgraduate School of Oncology, University, Milan, Italy
Type of business or sector	University

Education and training

Dates	2023
Title of qualification awarded	Certificate of Management revalidation for Medical Unit Directors
Principal subjects/occupational skills covered	Health management, Direction of hospital units
Name and type of organisation providing education and training	Accademia PoliS Lombardia, Milano
Dates	2020
Title of qualification awarded	National scientific qualification to the role of Full Professor
Principal subjects/occupational skills covered	▪ Macro-area 06/MEDS-09 - "Blood Diseases, Oncology and Rheumatology"
Name and type of organisation providing education and training	Education, University and Research Italian Ministry
Dates	2015
Title of qualification awarded	Certificate of Management for Medical Unit Directors
Principal subjects/occupational skills covered	Health management, Direction of hospital units
Name and type of organisation providing education and training	Eupolis Lombardia – School of Health Management, Milano

Dates 1994

Title of qualification awarded **European Certification on Medical Oncology**

Principal subjects/occupational skills covered Medical oncology

Name and type of organisation providing education and training European Society for Medical Oncology (ESMO)

Dates From 1987 to 1990

Title of qualification awarded **Postgraduate certificate in Clinical Oncology**

Principal subjects/occupational skills covered Clinical oncology

Name and type of organisation providing education and training University, Parma, Italy

Level in national or international classification ISCED 5A (Field of Education: 72)

Dates From 1984 to 1987

Title of qualification awarded **Postgraduate certificate in Haematology**

Principal subjects/occupational skills covered Haematology

Name and type of organisation providing education and training University, Milano, Italy

Level in national or international classification ISCED 5A (Field of Education: 72)

Dates 1984

Title of qualification awarded **Italian Medical Licence**

Principal subjects/occupational skills covered Medicine

Name and type of organisation providing education and training University, Milano, Italy

Dates From 1977 to 1984

Title of qualification awarded **Medical Degree** (cum laude)

Principal subjects/occupational skills covered Medicine

Name and type of organisation providing education and training University, Milano, Italy

Level in national or international classification ISCED 5A (Field of Education: 72)

Personal skills and competences

Mother tongue(s) **Italian**

Other language(s)

Self-assessment

European level ()*

English

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user

(*) Common European Framework of Reference for Languages

Additional information

- From 2023, **Secretary of the Ethics Committee Lombardia 4** of Lombardia Region, previously Secretary of the Ethics Committee of Istituto Nazionale Tumori, Milano, Italy, from 2005 to 2023
- **Coordinator of the Rare Cancers Working Group** of the European Society for Medical Oncology (ESMO); previously member of the executive Board of ESMO from 2005 to 2010 as Treasurer, from 2011 to 2015 as Chair of the Public Policy Committee, from 2016 to 2018 as Chair of the Public Policy Steering Committee and the EU Policy Committee, in 2019 as Director of the Public Policy Division
- **Sarcoma Faculty member** (coordinator from 2006 to 2011) of the European Society for Medical Oncology (ESMO)
- Member of the Board of Directors of the *European CanCer Organization* (ECCO) from 2014 to 2015
- Member of the Board of Directors of the *Connective Tissue Oncology Society* (CTOS), from 2017 to 2019
- Coordinator of the Steering committee of *Rare Cancers Europe* from 2008 to 2022
- **Coordinator of the Joint Action on Networks of Expertise (JANE) of the European Union**, ongoing from 2022
- Coordinator of the *Joint Action on Rare Cancers* (JARC) of the European Union, carried out from 2017 to 2019
- Coordinator of the **Sarcoma domain** of the *European Reference Network for Adult Rare Solid Cancers* (EURACAN) from 2017 to present
- **Member of the Coordination group of the Italian National Network on Rare Cancers**
- **Member of the Coordinating body of the Regional Oncology Network of Lombardia Region**
- **Member of the Technical-Scientific Committee of the Italian Sarcoma Group (ISG)** from 2022 to present; previously Secretary of the group from October 2002 to June 2021
- **Member of the EORTC Soft Tissue and Bone Sarcoma Group**
- Member from 2006 to 2009 (and Track leader in 2009) of the Cancer Education Committee of the *American Society of Clinical Oncology* (ASCO)
- Member of the Board of the *Federation of Italian Cooperative Oncology Groups* (FICOG), on behalf of the Italian Sarcoma Group from 2015 to 2021
- Founder and co-Editor in chief of *Clinical Sarcoma Research* (<http://www.clinicalsarcomaresearch.com>) from 2011 to 2020
- **Member of the Editorial Board of Annals of Oncology**
- Member of the following professional/scientific societies:
 - *European Society for Medical Oncology* (ESMO)
 - *Italian Association of Medical Oncology* (AIOM)
 - *American Society of Clinical Oncology* (ASCO)
 - *Connective Tissue Oncology Society* (CTOS)
 - *Society for Medical Decision Making* (SMDM)

Publications: see Annexes 1-2-3

Annexes

Annex 1: List of **Medline-indexed scientific publications, in English**

Annex 2: List of **Book chapters, in English**

Annex 3: List of **Books**

Annex 1

List of Medline-indexed scientific publications, in English

h-index: 106 (Scopus)

1. Vanzulli A, Vigorito R, Buonomenna C, Palmerini E, Quagliuolo V, Broto JM, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Diaz Beveridge R, Ferraresi V, Lugowska I, Pizzamiglio S, Verderio P, Duroni V, Fontana V, Donati DM, Palassini E, Bianchi G, Bertuzzi A, Buonadonna A, Pasquali S, Dei Tos AP, **Casali PG**, Morosi C, Stacchiotti S, Gronchi A. Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STs 1001, a randomized clinical trial. **ESMO Open**. 2025 Mar;10(3):104299.
2. **Casali PG**, Antoine-Poirel H, Berrocioso S, Blay JY, Dubois T, Ferrari A, Fullaondo A, Hovig E, Jagodzińska-Mucha P, Ługowska I, Kaasa S, Nicoară D, Pletsa V, Provenzano S, Santoro M, Šekerija M, Van Hoof W, Vyas M, Trama A; JANE Consortium. Health networking on cancer in the European Union: a 'green paper' by the EU Joint Action on Networks of Expertise (JANE). **ESMO Open**. 2025 Jan 27;10(2):104126. doi: 10.1016/j.esmoop.2024.104126. Online ahead of print.
3. Vincenzi B, Olimpieri PP, Celant S, Mazzocca A, Cortellini A, Comandone A, Tomassini L, Di Segni S, Russo P, **Casali PG**. Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry. **ESMO Open**. 2024 Dec;9(12):103995. doi: 10.1016/j.esmoop.2024.103995. Epub 2024 Nov 27.
4. Craparotta I, Mannarino L, Zadro R, Ballabio S, Marchini S, Pavesi G, Russo M, Renne SL, Meroni M, Ponzo M, Bello E, Sanfilippo R, **Casali PG**, D'Incalci M, Frapolli R. Mechanism of efficacy of trabectedin against myxoid liposarcoma entails detachment of the FUS-DDIT3 transcription factor from its DNA binding sites. **J Exp Clin Cancer Res**. 2024 Nov 26;43(1):309. doi: 10.1186/s13046-024-03228-z.
5. Sigalotti L, Frezza AM, Sbaraglia M, Del Savio E, Baldazzi D, Valenti B, Bellan E, De Benedictis I, Doni M, Gambarotti M, Vincenzi B, Brunello A, Baldi GG, Palmerini E, Pasquali S, Ciuffetti ME, Varano V, Cappello F, Appolloni V, Pastrello C, Jurisica I, Gronchi A, Stacchiotti S, **Casali PG**, Dei Tos AP, Maestro R. Proximal and Classic Epithelioid Sarcomas are Distinct Molecular Entities Defined by MYC/GATA3 and SOX17/Endothelial Markers, Respectively. **Mod Pathol**. 2025 Jan;38(1):100647.
6. Gennaro M, Mariani L, Palassini E, Stacchiotti S, Sangalli C, Listorti C, Vingiani A, Cortinovis U, Collini P, Allajbej A, Fiore M, **Casali PG**, Folli S, Gronchi A. Timeline of surgery in localized angiosarcoma of the breast: Improving outcome following multidisciplinary treatment optimization. **Eur J Surg Oncol**. 2024 Dec;50(12):108699. doi: 10.1016/j.ejso.2024.108699. Epub 2024 Sep 17.
7. Ray-Coquard I, **Casali PG**, Croce S, Fennessy FM, Fischerova D, Jones R, Sanfilippo R, Zapardiel I, Amant F, Blay JY, Martin-Broto J, Casado A, Chiang S, Dei Tos AP, Haas R, Hensley ML, Hohenberger P, Kim JW, Kim SI, Meydanli MM, Pautier P, Abdul Razak AR, Sehouli J, van Houdt W, Planchamp F, Friedlander M. ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas. **Int J Gynecol Cancer**. 2024 Sep 25;ijgc-2024-005823.
8. Stacchiotti S, Martini S, Pasquali S, Frezza AM, Beretta A, Percio S, Lecchi M, Tortoreto M, Barisella M, Collini P, Dagrada GP, Merlini A, Huang PH, Jenks A, Jones RL, Tap WD, Ingrosso M, Morosi C, Brich S, Giani C, Verderio P, **Casali PG**, Leonard H, Gronchi A, Zuco V, Zaffaroni N. GDF-15 predicts epithelioid hemangioendothelioma aggressiveness and is down-regulated by sirolimus through ATF4/ATF5 suppression. **Clin Cancer Res**. 2024 Sep 16.
9. Frezza AM, Leonard H, Aggerholm-Pedersen N, Badalamenti G, Baili P, Baldi GG, Bauer S, Bazzurri S, Benzonelli I, Bertuzzi A, Blay JY, Bianchi G, Bonfarnuzzo S, Bouvier C, Boye K, Martin Broto J, Brunello A, Campanacci D, **Casali PG**, Cicala C, Crotti E, D'Ambrosio L, Dei Tos AP, Dieckmann N, Dufresne A, Elston S, Ferraresi V, Gabellini S, Giani C, Giannusa V, Gil Sanjines M, Grassani T, Gronchi A, Lasalvia P, Lindskog S, Hindi N, Ingrosso M, Ivanescu A, Jones R, Lugowska I, Ketzer J, Mariuk-Jarema A, Mazzocca A, Monteleone L, Morosi C, Napolitano A, Nardozza F, Neri E, Nilsson M, Papakonstantinou A, Pasquali S, Sbaraglia M, Scolari F, Szkandera J, Valverde C, Vincenzi B, Vizzaccaro S, Zuccheri F, Stacchiotti S, Trama A. The observational EURACAN prospective clinical registry dedicated to epithelioid hemangioendothelioma: The protocol of an international and collaborative effort on an ultra-rare entity. **PLoS One**. 2024 Aug 12;19(8):e0308387.
10. Fabbroni C, Grignani G, Vincenzi B, Fumagalli E, De Pas TM, Mazzocca A, Pantaleo MA, Brunello A, Baldi GG, Boglione A, Fatigoni S, Berruti A, Giordano M, Marrari A, Dei Tos AP, Alberton AS, Aliberti S, Carlucci L, Rulli E, **Casali PG**, Sanfilippo R. TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group. **ESMO Open**. 2024 Aug;9(8):103667.
11. Pasquali S, Vallacchi V, Lalli L, Collini P, Barisella M, Romagosa C, Bague S, Coindre JM, Dei Tos AP, Palmerini E, Quagliuolo V, Martin-Broto J, Lopez-Pousa A, Grignani G, Blay JY, Beveridge RD, Casiraghi E, Brich S, Renne SL, Bergamaschi L, Vergani B, Sbaraglia M, **Casali PG**, Rivoltini L, Stacchiotti S, Gronchi A. Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy. **EBioMedicine**. 2024 Aug;106:105220.

12. Palassini E, Baldi GG, Ciniselli CM, Gennaro M, Gronchi A, Sangalli C, Conforti F, Collini P, Frezza AM, Pellegrini I, Allajbej A, Fiore M, Morosi C, Pennacchioli E, Barisella M, **Casali PG**, Verderio P, De Pas T, Stacchiotti S. Outcome improvement with chemotherapy and radiotherapy in primary, localized, radiation-associated angiosarcoma of the breast region: a retrospective case series analysis. **ESMO Open**. 2024 Jun;9(6):103474.
13. Franza A, Fabbroni C, Pasquali S, **Casali PG**, Sanfilippo R. New targeted therapies in liposarcoma: state of art and future perspectives. **Curr Opin Oncol**. 2024 Jul 1;36(4):291-296.
14. Palassini E, Baldi GG, Sulfaro S, Barisella M, Bianchi G, Campanacci D, Fiore M, Gambarotti M, Gennaro M, Morosi C, Navarra F, Palmerini E, Sangalli C, Sbaraglia M, Trama A, Asaferi S, Badalamenti G, Bertulli R, Bertuzzi AF, Biagini R, Bonadonna A, Brunello A, Callegaro D, Cananzi F, Cianchetti M, Collini P, Comandini D, Curcio A, D'Ambrosio L, De Pas T, Dei Tos AP, Ferraresi V, Ferrari A, Franchi A, Frezza AM, Fumagalli E, Ghilli M, Greto D, Grignani G, Guida M, Ibrahim T, Krengli M, Luksch R, Marrari A, Mastore M, Merlini A, Milano GM, Navarra P, Pantaleo MA, Parafioriti A, Pellegrini I, Pennacchioli E, Rastrelli M, Setola E, Tafuto S, Turano S, Valeri S, Vincenzi B, Vitolo V, Ivanescu A, Paloschi F, **Casali PG**, Gronchi A, Stacchiotti S. Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group. **Cancer Treat Rev**. 2024 May;126:102722.
15. De Luca I, Miliziano D, Guerra G, Colombo R, Morosi C, Sposito C, Fiore M, Venturelli E, Sangalli C, **Casali PG**, Cavalleri A, Fumagalli E. Hemodialysis and imatinib: Plasma levels, efficacy and tolerability in a patient with metastatic GIST - Case report. **Heliyon**. 2024 Mar 27;10(7):e28494.
16. Franza A, Gusmaroli E, Fabbroni C, Vigorito R, Pasquali S, **Casali PG**, Sanfilippo RG. Long-term disease stability with bicalutamide in a man with aggressive angiomyxoma: case report and state of art. **Front Oncol**. 2024 Jan 16;13:1260668.
17. Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Pizzamiglio S, Verderio P, Fontana V, Donati DM, Palassini E, Sanfilippo R, Bianchi G, Bertuzzi A, Morosi C, Pasquali S, Stacchiotti S, Bagué S, Coindre JM, Miceli R, Dei Tos AP, **Casali PG**. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG). **J Clin Oncol**. 2024 Jan 17;JCO2300908 [online ahead of print.PMID]
18. Stacchiotti S, Baldi GG, Frezza AM, Morosi C, Greco FG, Collini P, Barisella M, Dagrada GP, Zaffaroni N, Pasquali S, Gronchi A, Huang P, Ingrosso M, Tinè G, Miceli R, **Casali PG**. Regorafenib in advanced solitary fibrous tumour: Results from an exploratory phase II clinical study. **Eur J Cancer**. 2023 Dec;195:113391.
19. Sanfilippo R, Sbaraglia M, Fabbroni C, Croce S, Ray-Coquard I, Guermazi FV, Paolini B, Blanc-Durand F, Lecesne A, Chiappa V, Dei Tos AP, **Casali PG**. Low-grade uterine Leiomyosarcoma is highly sensitive to hormonal treatment. **Clin Cancer Res**. 2023 Sep 12. Online ahead of print.
20. Danieli M, Barretta F, Radaelli S, Fiore M, Sangalli C, Barisella M, Palassini E, Miceli R, Frezza AM, Callegaro D, Collini P, **Casali PG**, Stacchiotti S, Gronchi A. Pathological and radiological response following neoadjuvant treatments in primary localized resectable myxofibrosarcoma and undifferentiated pleomorphic sarcoma of the extremities and trunk wall. **Cancer**. 2023 Nov 1;129(21):3417-3429.
21. Sanfilippo R, Hindi N, Cruz Jurado J, Blay JY, Lopez-Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón-Perez I, Sangalli C, Pérez Aguiar JL, Romero J, Morosi C, Sunyach MP, Fabbroni C, Romagosa C, Ranchere-Vince D, Dei Tos AP, **Casali PG**, Martin-Broto J, Gronchi A. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial. **JAMA Oncol**. 2023 Mar 30:e230056.
22. Giani C, Radaelli S, Miceli R, Gandola L, Sangalli C, Frezza AM, Provenzano S, Pasquali S, Bertulli R, Fiore M, Callegaro D, Casanova M, Chiaravalli S, Collini P, Dagrada GP, Morosi C, Zaffaroni N, **Casali PG**, Ferrari A, Gronchi A, Stacchiotti S. Long-term survivors with desmoplastic small round cell tumor (DSRCT): Results from a retrospective single-institution case series analysis. **Cancer Med**. 2023 Mar 23.
23. Palmerini E, Sanfilippo R, Grignani G, Bonadonna A, Romanini A, Badalamenti G, Ferraresi V, Vincenzi B, Comandone A, Pizzolorusso A, Brunello A, Gelsomino F, De Pas T, Ibrahim T, Gurrieri L, Grosso F, Zanelli F, Pantaleo MA, Milesi L, Ciuffreda L, Ferrari V, Marchesi E, Quattrini I, Righi A, Setola E, Carretta E, **Casali PG**, Picci P, Ferrari S. Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis. **Front Oncol**. 2022 Dec 8;12:1042479.
24. Prades J, Trama A, **Casali PG**, Emile JF, Gaspar N, Janavicius R, Jančiauskienė R, Karjalainen S, Kopeckova K, Pylkkänen L, Svoboda M, Borrás JM. Is rare cancer care organized at national health system level? Multiple case study in six EU countries. **Eur J Public Health**. 2022 Nov 14:ckac166.
25. Sanchini V, Crico C, **Casali PG**, Pravettoni G. Measuring the impact of clinical ethics support services: further points for consideration. **J Med Ethics**. 2022 Nov;48(11):877-878.
26. Vincenzi B, Napolitano A, Comandone A, Sanfilippo R, Celant S, Olimpieri PP, Di Segni S, Russo P, **Casali PG**. Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry. **Int J Cancer**. 2022 Oct 4. doi: 10.1002/ijc.34309.
27. Hidalgo-Ríos S, Carrillo-García J, Moura DS, Stacchiotti S, López-Pousa A, Redondo A, Italiano A, Gutiérrez A, Grignani G, Hindi N, López-Guerrero JA, Muro XGD, Trufero JM, Palmerini E, García AS, Bernabeu D, Le Cesne A, **Casali PG**, Blay JY, Cruz Jurado J, Martin-Broto J. Peripheral Inflammatory Indexes

- Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib. **Cancers** (Basel). 2022 Aug 29;14(17):4186.
28. Stacchiotti S, Maria Frezza A, Demetri GD, Blay JY, Bajpai J, Baldi GG, Baldini EH, Benjamin RS, Bonvalot S, Bovée JVMG, Callegaro D, **Casali PG**, D'Angelo SP, Davis EJ, Dei Tos AP, Demicco EG, Desai J, Dileo P, Eriksson M, Gelderblom H, George S, Gladdy RA, Gounder MM, Gupta AA, Haas R, Hayes A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleiner ES, Le Cesne A, Maestro R, Martin Broto J, Maki RG, Miah AB, Palmerini E, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Strauss SJ, Tap WD, Thomas DM, Trama A, Trent JC, van der Graaf WTA, van Houdt WJ, von Mehren M, Wilky BA, Fletcher CDM, Gronchi A, Miceli R, Wagner AJ. Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. **Cancer Treat Rev**. 2022 Nov;110:102455.
 29. Nasca V, Frezza AM, Morosi C, Buonomenna C, Parafioriti A, Zappalà G, Bini F, **Casali PG**, Loppini M, Stacchiotti S. Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature. **Front Oncol**. 2022 Jul 19;12:953149.
 30. Frezza AM, Stacchiotti S, Chibon F, Coindre JM, Italiano A, Romagnosa C, Bagué S, Dei Tos AP, Braglia L, Palmerini E, Quagliuolo V, Broto JM, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Beveridge RD, Lugowska I, Lesluyes T, Maestro R, Merlo FD, **Casali PG**, Gronchi A. CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study. **Cancer Med**. 2022 Jul 18.
 31. Crico C, Sanchini V, **Casali PG**, Pravettoni G. Ethical issues in oncology practice: a qualitative study of stakeholders' experiences and expectations. **BMC Med Ethics**. 2022 Jun 30;23(1):67.
 32. Colombo C, Fiore M, Grignani G, Tolomeo F, Merlini A, Palassini E, Collini P, Stacchiotti S, **Casali PG**, Perrone F, Mariani L, Gronchi A. A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis. **Clin Cancer Res**. 2022 Sep 15;28(18):4027-4032.
 33. Palmerini E, Meazza C, Tamburini A, Bisogno G, Ferraresi V, Asafei SD, Milano GM, Coccoli L, Manzitti C, Luksch R, Serra M, Gambarotti M, Donati DM, Scotlandi K, Bertulli R, Favre C, Longhi A, Abate ME, Perrotta S, Mascarini M, D'Angelo P, Cesari M, Staats EL, Marchesi E, Carretta E, Ibrahim T, **Casali PG**, Picci P, Fagioli F, Ferrari S. Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2). **Cancer**. 2022 Feb 24.
 34. Palassini E, Mir O, Grignani G, Vincenzi B, Gelderblom H, Sebio A, Valverde C, Baldi GG, Brunello A, Cardellino GG, Marrari A, Badalamenti G, Martin-Broto J, Ferraresi V, Libertini M, Turano S, Gataa I, Collini P, Tos APD, Gennaro M, Bini F, Provenzano S, Vullo SL, Mariani L, Le Cesne A, **Casali PG**. Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses. **Breast Cancer Res Treat**. 2022 Feb 12.
 35. **Casali PG**, Licitra L, Frezza AM, Trama A. "Rare cancers": not all together in clinical studies! **Ann Oncol**. 2022 Feb 4:S0923-7534(22)00104-1.
 36. Baldi GG, Lo Vullo S, Grignani G, Vincenzi B, Badalamenti G, Mastore M, Buonomenna C, Morosi C, Barisella M, Frezza AM, Provenzano S, Simeone N, Picozzi F, Mariani L, **Casali PG**, Stacchiotti S. Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network. **Cancer**. 2022 Jan 13.
 37. Danieli M, Barretta F, Fiore M, Radaelli S, Sangalli C, Barisella M, Stacchiotti S, Palassini E, Miceli R, Frezza AM, Callegaro D, **Casali PG**, Gronchi A. Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall: Outcome Improvement Over Time at a Single Institution. **Ann Surg Oncol**. 2022 Jan 8.
 38. Danieli M, Barretta F, Fiore M, Radaelli S, Sangalli C, Barisella M, Stacchiotti S, Palassini E, Miceli R, Frezza AM, Callegaro D, **Casali PG**, Gronchi A. ASO Visual Abstract: Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall-Outcome Improvement over Time at a Single Institution. **Ann Surg Oncol**. 2022 Jan 3.
 39. Pasquali S, Palmerini E, Quagliuolo V, Martin-Broto J, Lopez-Pousa A, Grignani G, Brunello A, Blay JY, Tondero O, Diaz-Beveridge R, Ferraresi V, Lugowska I, Infante G, Braglia L, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Miceli R, **Casali PG**, Gronchi A. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. **Cancer**. 2022 Jan 1;128(1):85-93. Epub 2021 Oct 13.
 40. Vincenzi B, Napolitano A, Fiocco M, Mir O, Rutkowski P, Blay JY, Reichardt P, Joensuu H, Fumagalli E, Gennatas S, Hindi N, Nannini M, Spalato Ceruso M, Italiano A, Grignani G, Brunello A, Gasperoni S, De Pas T, Badalamenti G, Pantaleo MA, van Houdt WJ, IJzerman NS, Steeghs N, Gelderblom H, Desai IME, Falkenhorst J, Silletta M, Sbaraglia M, Tonini G, Martin-Broto J, Hohenberger P, Le Cesne A, Jones RL, Dei Tos AP, Gronchi A, Bauer S, **Casali PG**. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. **Clin Cancer Res**. 2021 Oct 6.

41. **Casali PG**, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dufresne A, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Strauss SJ, Hall KS, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Gronchi A, Stacchiotti S; ESMO Guidelines Committee, EURACAN and GENTURIS. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2022 Jan;33(1):20-33.
42. Martin-Broto J, Lopez-Alvarez M, Moura DS, Ramos R, Collini P, Romagosa C, Bague S, Renne SL, Barisella M, Velasco V, Coindre JM, Lopez-Lopez D, Dopazo J, Gambarotti M, Braglia L, Merlo DF, Palmerini E, Stacchiotti S, Quagliuolo VL, Lopez-Pousa A, Grignani G, Blay JY, Brunello A, Gutierrez A, Valverde C, Hindi N, Dei Tos AP, Picci P, **Casali PG**, Gronchi A. Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STIS 1001 Randomized Phase III Trial. **Mol Cancer Ther**. 2021 Dec;20(12):2539-2552.
43. Strauss SJ, Frezza AM, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, de Álava E, Dei Tos AP, Garcia Del Muro X, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Gaspar N, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Gronchi A, Haas R, Hassan AB, Hecker-Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, López Pousa A, Martin-Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morland B, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Sundby Hall K, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Ladenstein R, **Casali PG**, Stacchiotti S; ESMO Guidelines Committee, EURACAN, GENTURIS and ERN PaedCan. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. **Ann Oncol**. 2021 Dec;32(12):1520-1536.
44. Mannarino L, Craparotta I, Ballabio S, Frapolli R, Meroni M, Bello E, Panini N, Callari M, Sanfilippo R, **Casali PG**, Barisella M, Fabbioni C, Marchini S, D'Incalci M. Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma. **Genomics**. 2021 Sep;113(5):3439-3448.
45. Danieli M, Barretta F, Fiore M, Radaelli S, Sangalli C, Barisella M, Stacchiotti S, Palassini E, Miceli R, Callegaro D, **Casali PG**, Gronchi A. Unplanned excision of extremity and trunk wall soft tissue sarcoma: to re-resect or not to re-resect? **Ann Surg Oncol**. 2021 Aug;28(8):4706-4717.
46. Zuco V, Pasquali S, Tortoreto M, Brich S, Percio S, Dagrada GP, Colombo C, Sanfilippo R, Lauricella C, Gounder M, El Bezawy R, Barisella M, Dei Tos AP, **Casali PG**, Gronchi A, Stacchiotti S, Zaffaroni N. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation. **J Exp Clin Cancer Res**. 2021 Mar 1;40(1):83.
47. Frezza AM, Ravi V, Lo Vullo S, Vincenzi B, Tolomeo F, Chen TW, Teterycz P, Baldi GG, Italiano A, Penel N, Brunello A, Duffaud F, Hindi N, Iwata S, Smrke A, Fedenko A, Gelderblom H, Van Der Graaf W, Vozy A, Connolly E, Grassi M, Benjamin RS, Broto JM, Grignani G, Jones RL, Kawai A, Tysarowski A, Mariani L, **Casali PG**, Stacchiotti S. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. **Cancer Med**. 2021 Apr;10(8):2645-2659.
48. Frezza AM, Napolitano A, Miceli R, Badalamenti G, Brunello A, Buonomenna C, **Casali PG**, Caraceni A, Grignani G, Gronchi A, Infante G, Morosi C, Saita L, Simeone N, Zaffaroni N, Vincenzi B, Stacchiotti S. Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network. **ESMO Open**. 2021 Apr;6(2):100083.
49. Fabbioni C, Fucà G, Ligorio F, Fumagalli E, Barisella M, Collini P, Morosi C, Gronchi A, Dei Tos AP, **Casali PG**, Sanfilippo R. Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin. **Cancers** (Basel). 2021 Mar 22;13(6):1453.
50. Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovee JVMG, Callegaro D, **Casali PG**, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque López MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. **Cancer**. 2021 Aug 15;127(16):2934-2942.

51. Stacchiotti S, Miah AB, Frezza AM, Messiou C, Morosi C, Caraceni A, Antonescu CR, Bajpai J, Baldini E, Bauer S, Biagini R, Bielack S, Blay JY, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Callegaro D, De Alava E, Deoras-Sutliff M, Dufresne A, Eriksson M, Errani C, Fedenko A, Ferraresi V, Ferrari A, Fletcher CDM, Garcia Del Muro X, Gelderblom H, Gladdy RA, Gouin F, Grignani G, Gutkovich J, Haas R, Hindi N, Hohenberger P, Huang P, Joensuu H, Jones RL, Jungels C, Kasper B, Kawai A, Le Cesne A, Le Grange F, Leithner A, Leonard H, Lopez Pousa A, Martin Broto J, Merimsky O, Merriam P, Miceli R, Mir O, Molinari M, Montemurro M, Oldani G, Palmerini E, Pantaleo MA, Patel S, Piperno-Neumann S, Raut CP, Ravi V, Razak ARA, Reichardt P, Rubin BP, Rutkowski P, Safwat AA, Sangalli C, Sapisochin G, Sbaraglia M, Scheipl S, Schöffski P, Strauss D, Strauss SJ, Sundby Hall K, Tap WD, Trama A, Tweddle A, van der Graaf WTA, Van De Sande MAJ, Van Houdt W, van Oortmerssen G, Wagner AJ, Wartenberg M, Wood J, Zaffaroni N, Zimmermann C, **Casali PG**, Dei Tos AP, Gronchi A. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. **ESMO Open**. 2021 Jun;6(3):100170.
52. Zanchetta E, Ciniselli CM, Bardelli A, Colombo C, Stacchiotti S, Baldi GG, Provenzano S, Bertulli R, Bini F, Casale A, Greco FG, Ferrari A, Verderio P, Fiore M, Gronchi A, **Casali PG**, Morosi C, Palassini E. Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis. **Cancer Med**. 2021 Jul;10(13):4356-4365.
53. Bini F, Fiore M, Provenzano S, Bertulli R, Ottini A, Colombo C, Vitellaro M, Greco G, Morosi C, Gronchi A, **Casali PG**, Palassini E. Management of serious complications in intra-abdominal desmoid-type fibromatosis. **Cancer Rep (Hoboken)**. 2021 Jun 24:e1411.
54. Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, De Álava E, Del Muro XG, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hecker-Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Mir O, Montemurro M, Morland B, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Strauss S, Sundby Hall K, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, **Casali PG**, Stacchiotti S; ESMO Guidelines Committee, EURACAN and GENTURIS. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2021 Jul 21:S0923-7534(21)02184-0.
55. **Casali PG**, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Penel N, Hartmann JT, Duffaud F, Goldstein D, Martin Broto J, Gronchi A, Wardelmann E, Marréaud S, Zalcberg JR, Litière S, Blay J-Y. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS). **Ann Oncol** 2021, in press
56. Crico C, Sanchini V, **Casali PG**, Pravettoni G. Evaluating the effectiveness of clinical ethics committees: a systematic review. **Med Health Care Philos**. 2020 Nov 21. [Epub ahead of print]
57. Stacchiotti S, Simeone N, Lo Vullo S, Baldi GG, Brunello A, Vincenzi B, Palassini E, Dagrada G, Collini P, Morosi C, Greco FG, Sbaraglia M, Dei Tos AP, Mariani L, Frezza AM, **Casali PG**. Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian rare cancer network. **Cancer**. 2020 Oct 27. [Epub ahead of print]
58. **Casali PG**, Vyas M; European Society for Medical Oncology (ESMO). Data protection and research in the European Union: a major step forward, with a step back. **Ann Oncol**. 2020 Oct 20 [Epub ahead of print]
59. **Casali PG**, Dei Tos AP, Gronchi A. When does a new sarcoma exist? **Clin Sarcoma Res**. 2020 Sep 13;10:19.
60. Fucà G, Fabbri C, Mancari R, Manglaviti S, Bogani G, Fumagalli E, Bertulli R, Morosi C, Collini P, Raspagliesi F, Colombo N, **Casali PG**, Sanfilippo R. Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers. **Clin Sarcoma Res**. 2020 Aug 28;10:17.
61. Raimondi A, Simeone N, Guzzo M, Maniezzo M, Collini P, Morosi C, Greco FG, Frezza AM, **Casali PG**, Stacchiotti S. Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review. **ESMO Open**. 2020 Jul;5(4):e000663.
62. Sanfilippo R, Fabbri C, Fucà G, Fumagalli E, Morosi C, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, **Casali PG**. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors. **Clin Cancer Res**. 2020 Oct 15;26(20):5534-5538.
63. Baldi GG, Brahmi M, Lo Vullo S, Cojocar E, Mir O, Casanova M, Vincenzi B, De Pas TM, Grignani G, Pantaleo MA, Blay JY, Jones RL, Le Cesne A, Frezza AM, Gronchi A, Collini P, Dei Tos AP, Morosi C, Mariani L, **Casali PG**, Stacchiotti S. The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. **Oncologist**. 2020 Jun 25.
64. Ray-Coquard I, Hatcher H, Bompas E, Casado A, Westermann A, Isambert N, **Casali PG**, Pratap S, Stark D, Valverde C, Anand A, Huizing M, Floquet A, Lindner L, Hermes B, Seddon B, Coens C, Jones R, Reed N. A

randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113). **Int J Gynecol Cancer**. 2020 Oct;30(10):1633-1637.

65. Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Braglia L, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, **Casali PG**. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. **J Clin Oncol**. 2020 Jul 1;38(19):2178-2186.
66. Sanfilippo R, Jones RL, Blay JY, Le Cesne A, Provenzano S, Antoniou G, Mir O, Fucà G, Fumagalli E, Bertulli R, Stacchiotti S, Brahmi M, Grosso F, Dufresne A, Hindi N, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, **Casali PG**. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). **Clin Cancer Res**. 2019 Sep 1;25(17):5295-5300.
67. **Casali PG**. Rare cancers: from centralized referral to networking. **Ann Oncol**. 2019 Jul 1;30(7):1037-1038.
68. Stacchiotti S, Zuco V, Tortoreto M, Cominetti D, Frezza AM, Percio S, Indio V, Barisella M, Monti V, Brich S, Astolfi A, Colombo C, Pasquali S, Folini M, Gounder MM, Pantaleo MA, Collini P, Dei Tos AP, **Casali PG**, Gronchi A, Zaffaroni N. Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft. **Cancers (Basel)**. 2019 Jul 19;11(7):1015.
69. Stacchiotti S, Ferrari S, Redondo A, Hindi N, Palmerini E, Vaz Salgado MA, Frezza AM, **Casali PG**, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, Morosi C, Brich S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. **Lancet Oncol**. 2019 Sep;20(9):1252-1262. Erratum in: *Lancet Oncol*. 2019 Oct;20(10):e559.
70. Bello E, Brich S, Craparotta I, Mannarino L, Ballabio S, Gatta R, Marchini S, Carrassa L, Matteo C, Sanfilippo R, Gronchi A, **Casali PG**, Pilotti S, D'Incalci M, Frapolli R. Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin. **Br J Cancer**. 2019 Sep;121(6):464-473. Erratum in: *Br J Cancer*. 2020 Mar;122(7):1120.
71. Frapolli R, Bello E, Ponzio M, Craparotta I, Mannarino L, Ballabio S, Marchini S, Carrassa L, Ubezio P, Porcu L, Brich S, Sanfilippo R, **Casali PG**, Gronchi A, Pilotti S, D'Incalci M. Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas. **Clin Cancer Res**. 2019 Dec 15;25(24):7565-7575. Erratum in: *Clin Cancer Res*. 2020 Mar 1;26(5):1199.
72. Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Teterycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desai I, Fedenko A, Maki RG, Jones RL, Benjamin RS, Blay JY, Kawai A, Gounder M, Gronchi A, Le Cesne A, Mir O, Czarnecka AM, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, **Casali PG**, Thornton K, Stacchiotti S. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. **Cancer**. 2020 Jan 1;126(1):98-104.
73. Callegaro D, Miceli R, Bonvalot S, Ferguson PC, Strauss DC, van Praag VVM, Levy A, Griffin AM, Hayes AJ, Stacchiotti S, Pèchoux CL, Smith MJ, Fiore M, Tos APD, Smith HG, Catton C, Szkandera J, Leithner A, van de Sande MAJ, **Casali PG**, Wunder JS, Gronchi A. Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. **EClinicalMedicine**. 2019 Nov 22;17:100215.
74. Martin-Broto J, Cruz J, Penel N, Le Cesne A, Hindi N, Luna P, Moura DS, Bernabeu D, de Alava E, Lopez-Guerrero JA, Dopazo J, Peña-Chilet M, Gutierrez A, Collini P, Karanian M, Redondo A, Lopez-Pousa A, Grignani G, Diaz-Martin J, Marcilla D, Fernandez-Serra A, Gonzalez-Aguilera C, **Casali PG**, Blay JY, Stacchiotti S. Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. **Lancet Oncol**. 2020 Mar;21(3):456-466.
75. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. **Eur J Cancer**. 2020 Mar;127:96-107.
76. Stahel RA, Lacombe D, Cardoso F, **Casali PG**, Negrouk A, Marais R, Hiltbrunner A, Vyas M; Clinical Academic Cancer Research Forum (CAREFOR). Current models, challenges and best practices for work conducted between European academic cooperative groups and industry. **ESMO Open**. 2020 Mar;5(2):e000628.
77. **Casali PG**, Trama A. Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU). **ESMO Open**. 2020 Mar;5(2):e000666.
78. Gronchi A, Bonvalot S, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom HJ, van Coevorden F, Penel N, Kopp HG, Duffaud F, Goldstein D, Broto JM, Wardelmann E, Marréaud S, Smithers M, Le Cesne A, Zaffaroni F, Litière S, Blay JY, **Casali PG**. Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. **JAMA Surg**. 2020 Apr 1;155(6):e200397 [Epub ahead of print]

79. Frezza AM, Sbaraglia M, Lo Vullo S, Baldi GG, Simeone N, Frenos F, Campanacci D, Stacchiotti S, Pasquali S, Callegaro D, Gambarotti M, Barisella M, Palomba A, Mariani L, **Casali PG**, Dei Tos AP, Gronchi A. The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group. **Eur J Surg Oncol**. 2020 Jul;46(7):1320-1326.
80. Radaelli S, Fossati P, Stacchiotti S, Akiyama T, Asencio JM, Bandiera S, Boglione A, Boland P, Bolle S, Bruland Ø, Brunello A, Bruzzi P, Campanacci D, Cananzi F, Capanna R, Casadei R, Cordoba A, Court C, Dei Tos AP, DeLaney TF, De Paoli A, De Pas TM, Desai A, Di Brina L, Donati DM, Fabbri N, Fiore MR, Frezza A, Gambarotti M, Gasbarrini A, Georg P, Grignani G, Hindi N, Hug EB, Jones R, Kawai A, Krol AD, Le Grange F, Luzzati A, Marquina G, Martin-Benlloch JA, Mazzocco K, Navarra F, Navarra P, Parchi PD, Patel S, Pennacchioli E, Petrongari MG, Picci P, Pollock R, Porcu L, Quagliuolo V, Sangalli C, Scheipl S, Scotto GM, Spalek M, Steinmeier T, Timmermann B, Trama A, Uhl M, Valverde C, Varga PP, Verges R, Weber DC, Zoccali C, **Casali PG**, Sommer J, Gronchi A. The sacral chordoma margin. **Eur J Surg Oncol**. 2020 Apr 27:S0748-7983(20)30425-X [Epub ahead of print]
81. Baldi GG, Brahmi M, Lo Vullo S, Cojocar E, Mir O, Casanova M, Vincenzi B, De Pas T, Grignani G, Pantaleo MA, Blay JY, Jones RL, Le Cesne A, Frezza AM, Gronchi A, Collini P, Dei Tos AP, Morosi C, Mariani L, **Casali PG**, Stacchiotti S. The activity of chemotherapy in inflammatory myofibroblastic tumour (IMT): a multicentre, European retrospective case series analysis. **Oncologist** 2020 Jun 25 [Epub ahead of print]
82. Gronchi A, Hindi N, Cruz J, Blay JY, Lopez-Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón I, Sangalli C, Pérez Aguiar JL, Romero J, Morosi C, Sunyach MP, Sanfilippo R, Romagosa C, Ranchere-Vince D, Dei Tos AP, **Casali PG**, Martin-Broto J. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. **EclinicalMedicine**. 2019;9:35-43.
83. Tirotta F, Fumagalli E, Colombo C, Morosi C, Barisella M, Radaelli S, Frezza AM, **Casali PG**, Gronchi A, Fiore M. Management of complicated tumor response to tyrosine-kinase inhibitors in gastrointestinal stromal tumors. **J Surg Oncol**. 2019 May 7 [Epub ahead of print]
84. Brenca M, Stacchiotti S, Fassetta K, Sbaraglia M, Janjusevic M, Racanelli D, Polano M, Rossi S, Brich S, Dagrada GP, Collini P, Colombo C, Gronchi A, Astolfi A, Indio V, Pantaleo MA, Picci P, **Casali PG**, Dei Tos AP, Pilotti S, Maestro R. NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskelatal myxoid chondrosarcomas. **J Pathol**. 2019 Apr 25 [Epub ahead of print]
85. Vyas M, de Vries EGE, **Casali PG**, Tabernero J. Shortages of inexpensive essential medicines. **Lancet Oncol**. 2019 May;20(5):e224-e225 [Epub ahead of print]
86. Urbini M, Indio V, Tarantino G, Ravegnini G, Angelini S, Nannini M, Saponara M, Santini D, Ceccarelli C, Fiorentino M, Vincenzi B, Fumagalli E, **Casali PG**, Grignani G, Pession A, Ardizzoni A, Astolfi A, Pantaleo MA. Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST. **Genes Chromosomes Cancer**. 2019 Mar 19. [Epub ahead of print]
87. Pasquali S, Pizzamiglio S, Touati N, Litiere S, Marreaud S, Kasper B, Gelderblom H, Stacchiotti S, Judson I, Dei Tos AP, Verderio P, **Casali PG**, Woll PJ, Gronchi A; EORTC – Soft Tissue and Bone Sarcoma Group. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. **Eur J Cancer**. 2019 Mar;109:51-60.
88. Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, **Casali PG**, Italiano A, Gutierrez A, Moura DS, Peña-Chilet M, Diaz-Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Garcia Del Muro X, Grignani G, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, Dei Tos AP, LeCesne A, Blay JY, Cruz J. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. **Lancet Oncol**. 2019 Jan;20(1):134-144.
89. Nizri E, Fiore M, Colombo C, Radaelli S, Callegaro D, Sanfilippo R, Sangalli C, Collini P, Morosi C, Stacchiotti S, **Casali PG**, Gronchi A. Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients-A propensity score analysis. **J Surg Oncol**. 2019 Mar;119(3):318-323.
90. Stacchiotti S, Simeone N, Lo Vullo S, Morosi C, Greco FG, Gronchi A, Barisella M, Collini P, Zaffaroni N, Dagrada GP, Frezza AM, Mariani L, **Casali PG**. Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. **Eur J Cancer**. 2019 Jan;106:225-233.
91. Fucà G, Hindi N, Ray-Coquard I, Colia V, Dei Tos AP, Martin-Broto J, Brahmi M, Collini P, Lorusso D, Raspagliesi F, Pantaleo MA, Vincenzi B, Fumagalli E, Gronchi A, **Casali PG**, Sanfilippo R. Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. **Oncologist**. 2018 Dec 5. pii: theoncologist.2018-0338. [Epub ahead of print]
92. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Le Pèchoux C, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Catton C, **Casali PG**, Wunder JS, Gronchi A. Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. **Eur J Cancer**. 2018 Dec;105:19-27.

93. Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M, Prunerì G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rosso L, Rea F, Pastorino U, **Casali PG**, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA; TYME network collaborators. Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignancieS (TYME). **Cancer Treat Rev**. 2018 Dec;71:76-87.
94. **Casali PG**, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2018 Oct 1;29(Supplement_4):iv79-iv95.
95. **Casali PG**, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2018 Oct 1;29(Supplement_4):iv268-iv269.
96. Stacchiotti S, Morosi C, Lo Vullo S, Casale A, Palassini E, Frezza AM, Dinoi G, Messina A, Gronchi A, Cavalleri A, Venturelli E, Morelli D, Pilotti S, Collini P, Brich S, Tamborini E, Mariani L, **Casali PG**. Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study. **Cancer**. 2018 Oct 15;124(20):4056-4063.
97. **Casali PG**, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2018 Oct 1;29(Supplement_4):iv267.
98. Vincenzi B, Nannini M, Badalamenti G, Grignani G, Fumagalli E, Gasperoni S, D'Ambrosio L, Incorvaia L, Stellato M, Spalato Ceruso M, Napolitano A, Valeri S, Santini D, Tonini G, **Casali PG**, Dei Tos AP, Pantaleo MA. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. **Ther Adv Med Oncol**. 2018 Aug 29;10:1758835918794623.
99. Stiller CA, Botta L, Brewster DH, Ho VKY, Frezza AM, Whelan J, **Casali PG**, Trama A, Gatta G; EUROCORE-5 Working Group. Survival of adults with cancers of bone or soft tissue in Europe-Report from the EUROCORE-5 study. **Cancer Epidemiol**. 2018 Oct;56:146-153.
100. Frezza AM, Lee ATJ, Nizri E, Sbaraglia M, Jones RL, Gronchi A, Dei Tos AP, **Casali PG**. 2018 ESMO Sarcoma and GIST Symposium: 'take-home messages' in soft tissue sarcoma. **ESMO Open**. 2018 Jun 28;3(4):e000390.
101. Urbini M, Indio V, Astolfi A, Tarantino G, Renne SL, Pilotti S, Dei Tos AP, Maestro R, Collini P, Nannini M, Saponara M, Murrone L, Dagrada GP, Colombo C, Gronchi A, Pession A, **Casali PG**, Stacchiotti S, Pantaleo MA. Identification of an Actionable Mutation of KIT in a Case of Extraskelatal Myxoid Chondrosarcoma. **Int J Mol Sci**. 2018 Jun 23;19(7).
102. Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desar IME, Benjamin RS, Blay JY, Broto JM, **Casali PG**, Gelderblom H, Grignani G, Gronchi A, Hall KS, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Philippe T, Picci P, Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. **JAMA Oncol**. 2018 Sep 1;4(9):e180219. Epub 2018 Sep 13.
103. Frezza AM, Trama A, Blay JY, **Casali PG**. Networking in rare cancers: What was done, what's next. **Eur J Surg Oncol**. 2019 Jan;45(1):16-18.

104. Raimondi A, Colombo F, Pintarelli G, Morosi C, Renne SL, Frezza AM, Saponara M, Dei Tos AP, Mazzocchi A, Provenzano S, **Casali PG**, Stacchiotti S. Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review. **Anticancer Drugs**. 2018 Jul;29(6):589-595.
105. Pasquali S, Colombo C, Pizzamiglio S, Verderio P, Callegaro D, Stacchiotti S, Martin Broto J, Lopez-Pousa A, Ferrari S, Poveda A, De Paoli A, Quagliuolo V, Jurado JC, Comandone A, Grignani G, De Sanctis R, Palassini E, Llombar-Bosch A, Dei Tos AP, **Casali PG**, Picci P, Gronchi A. High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. **Eur J Cancer**. 2018 Feb 20;93:28-36.
106. Fiore M, Ford S, Callegaro D, Sangalli C, Colombo C, Radaelli S, Frezza AM, Renne SL, **Casali PG**, Gronchi A. Adequate Local Control in High-Risk Soft Tissue Sarcoma of the Extremity Treated with Surgery Alone at a Reference Centre: Should Radiotherapy Still be a Standard? **Ann Surg Oncol**. 2018 Feb 22. [Epub ahead of print]
107. Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, **Casali PG**, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A. Global cancer control: responding to the growing burden, rising costs and inequalities in access. **ESMO Open**. 2018 Feb 2;3(2):e000285.
108. Nannini M, Nigro MC, Vincenzi B, Fumagalli E, Grignani G, D'Ambrosio L, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, **Casali PG**, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA. Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. **Ther Adv Med Oncol**. 2017 Dec;9(12):731-739.
109. Provenzano S, Raimondi A, Bertulli RM, Colia V, Renne SL, Collini P, Dagrada G, Callegaro D, Fiore M, Greco FG, **Casali PG**. Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor. **Clin Sarcoma Res**. 2017 Dec 28;7:20.
110. De Sanctis R, Giordano L, Colombo C, De Paoli A, Navarria P, Sangalli C, Buonadonna A, Sanfilippo R, Bertola G, Fiore M, Marrari A, Navarria F, Bertuzzi A, **Casali PG**, Basso S, Santoro A, Quagliuolo V, Gronchi A. Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303. **Ann Surg Oncol**. 2017 Dec;24(13):3872-3879.
111. Pasquali S, Bonvalot S, Tzanis D, **Casali PG**, Trama A, Gronchi A; RARECARENet Working Group. Treatment challenges in and outside a network setting: Soft tissue sarcomas. **Eur J Surg Oncol**. 2017 Sep 19. [Epub ahead of print]
112. Urbini M, Astolfi A, Indio V, Tarantino G, Serravalle S, Saponara M, Nannini M, Gronchi A, Fiore M, Maestro R, Brenca M, Dei Tos AP, Dagrada GP, Negri T, Pilotti S, **Casali PG**, Biasco G, Pession A, Stacchiotti S, Pantaleo MA. Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. **Oncotarget**. 2017 May 17;8(36):60036-60045.
113. Colia V, Fumagalli E, Provenzano S, Bertulli R, Stacchiotti S, Morosi C, Collini P, Gronchi A, **Casali PG**, Sanfilippo R. High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. **Sarcoma**. 2017;2017:3739159. Epub 2017 Aug 30.
114. Colia V, Fiore M, Provenzano S, Fumagalli E, Bertulli R, Morosi C, Tos APD, Barisella M, Gronchi A, **Casali PG**, Sanfilippo R. Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma. **Clin Sarcoma Res**. 2017 Aug 22;7:16.
115. Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, **Casali PG**, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. **ESMO Open**. 2017 Jan 16;1(6):e000142.
116. Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, **Casali PG**, Provenzano S, Kawai A. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. **Oncologist**. 2017 Jul 28. [Epub ahead of print]
117. Corino VDA, Montin E, Messina A, **Casali PG**, Gronchi A, Marchianò A, Mainardi LT. Radiomic analysis of soft tissues sarcomas can distinguish intermediate from high-grade lesions. **J Magn Reson Imaging**. 2017 Jun 27. [Epub ahead of print]
118. Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, **Casali PG**. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. **Lancet Oncol**. 2017 Jun;18(6):812-822
119. Pasquali S, Palassini E, Stacchiotti S, **Casali PG**, Gronchi A. Neoadjuvant treatment: a novel standard? **Curr Opin Oncol**. 2017 Jul;29(4):253-259

120. Palassini E, Frezza AM, Mariani L, Lalli L, Colombo C, Fiore M, Messina A, Casale A, Morosi C, Collini P, Stacchiotti S, **Casali PG**, Gronchi A. Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis. **Cancer J**. 2017 Mar/Apr;23(2):86-91.
121. MacNeill AJ, Gronchi A, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, **Casali PG**, Pollock RE, Barretta F, Raut CP, Strauss DC. Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report From the Transatlantic RPS Working Group. **Ann Surg**. 2017 Apr 7. [Epub ahead of print]
122. Urbini M, Astolfi A, Pantaleo MA, Serravalle S, Dei Tos AP, Picci P, Indio V, Sbaraglia M, Benini S, Righi A, Gambarotti M, Gronchi A, Colombo C, Dagrada GP, Pilotti S, Maestro R, Polano M, Saponara M, Tarantino G, Pession A, Biasco G, **Casali PG**, Stacchiotti S. HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma. **Genes Chromosomes Cancer**. 2017 Jul;56(7):582-586.
123. **Casali PG**, Zalcborg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schöffski P, Leyvraz S, Italiano A, Grünwald V, Pousa AL, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn P, Litière S, Marreaud S, van der Graaf W, Gronchi A, Verweij J; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. **J Clin Oncol**. 2017 May 20;35(15):1713-1720.
124. Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, **Casali PG**, D'Incalci M, Zaffaroni N. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. **Eur J Cancer**. 2017 May;76:84-92.
125. Marchesi E, Cagnazzo C, Quattrini I, Leopardi MP, Villa C, Grignani G, D'Ambrosio L, Stacchiotti S, **Casali PG**, Picci P. How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience. **Clin Sarcoma Res**. 2017 Feb 28;7:4.
126. Stacchiotti S, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, Gardner PA, Gelderblom H, Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, Vleggeert-Lankamp C, **Casali PG**, Sommer J. Best practices for the Management of Local-regional Recurrent Chordoma. A Position Paper by the Chordoma Global Consensus Group. **Ann Oncol**. 2017 Feb 9. [Epub ahead of print]
127. MacNeill AJ, Miceli R, Strauss DC, Bonvalot S, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, **Casali PG**, Pollock RE, Raut CP, Gronchi A, Swallow CJ. Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans-Atlantic RPS Working Group. **Cancer**. 2017 Jun 1;123(11):1971-1978.
128. Pantaleo MA, Urbini M, Indio V, Ravegnini G, Nannini M, De Luca M, Tarantino G, Angelini S, Gronchi A, Vincenzi B, Grignani G, Colombo C, Fumagalli E, Gatto L, Saponara M, Ianni M, Paterini P, Santini D, Pirini MG, Ceccarelli C, Altamari A, Gruppioni E, Renne SL, Collini P, Stacchiotti S, Brandi G, **Casali PG**, Pinna AD, Astolfi A, Biasco G. Genome-wide Analyses Identifies MEN1 and MAX Mutations and a Neuroendocrine-like Molecular Heterogeneity in Quadruple WT GIST. **Mol Cancer Res**. 2017 Jan 27 [Epub ahead of print]
129. Andritsch E, Beishon M, Bielack S, Bonvalot S, **Casali P**, Crul M, Bolton RD, Donati DM, Douis H, Haas R, Hogendoorn P, Kozhaeva O, Lavender V, Lovey J, Negrouk A, Pereira P, Roca P, de Lempdes GR, Saarto T, van Berck B, Vassal G, Wartenberg M, Yared W, Costa A, Naredi P. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. **Crit Rev Oncol Hematol**. 2017;110:94-105.
130. Demetri GD, Blay JY, **Casali PG**. Advances and controversies in the management of soft tissue sarcomas. **Future Oncol**. 2017;13(1s):3-11
131. Saponara M, Stacchiotti S, **Casali PG**, Gronchi A. (Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair. **Eur J Cancer**. 2017;70:1-11.
132. Raspagliesi F, Maltese G, Bogani G, Fucà G, Lepori S, De Iaco P, Perrone M, Scambia G, Cormio G, Bogliolo S, Bergamini A, Bifulco G, **Casali PG**, Lorusso D. Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study. **Gynecol Oncol**. 2016 Nov 4 [Epub ahead of print]
133. Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, Fiore M, Stacchiotti S, Dagrada GP, **Casali PG**, Gronchi A, Astolfi A, Pantaleo MA, Villa A, Lombardo C, Arienti F, Pilotti S, Rivoltini L, Castelli C. Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment. **J Invest Dermatol**. 2016 Sep 5 [Epub ahead of print]

134. Gronchi A, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch A, Dei Tos AP, Collini P, Jurado JC, De Paoli A, Donati DM, Poveda A, Quagliuolo V, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli S, Palassini E, **Casali PG**, Picci P. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. **Ann Oncol**. 2016 Oct 11 [Epub ahead of print]
135. Colia V, Provenzano S, Morosi C, Collini P, Renne SL, Dagrada PG, Sangalli C, Dei Tos AP, Marrari A, **Casali PG**, Stacchiotti S. Solitary fibrous tumour presenting with a single bone metastasis: report of six cases and literature review. **Clin Sarcoma Res**. 2016 Sep 1;6(1):16.
136. Radaelli S, Fiore M, Colombo C, Ford S, Palassini E, Sanfilippo R, Stacchiotti S, Sangalli C, Morosi C, **Casali PG**, Gronchi A. Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. **Surg Oncol**. 2016 Sep;25(3):125-31.
137. Stacchiotti S, Provenzano S, Dagrada G, Negri T, Brich S, Basso U, Brunello A, Grosso F, Galli L, Palassini E, Libertini M, Colia V, Gronchi A, Dei Tos AP, Crippa F, Morosi C, Pilotti S, **Casali PG**. Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. **Ann Surg Oncol**. 2016 Sep;23(9):2735-44.
138. Colia V, Provenzano S, Hindi N, **Casali PG**, Stacchiotti S. Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma. **Rep Pract Oncol Radiother**. 2016 Jul-Aug;21(4):361-9.
139. Stacchiotti S, Astolfi A, Gronchi A, Fontana A, Pantaleo MA, Negri T, Brenca M, Tazzari M, Urbini M, Indio V, Colombo C, Radaelli S, Brich S, Dei Tos AP, **Casali PG**, Castelli C, Dagrada GP, Pilotti S, Maestro R. Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss. **Mol Cancer Res**. 2016 Sep;14(9):820-9.
140. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Pechoux CL, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Mariani L, Wunder JS, Pollock RE, **Casali PG**, Gronchi A. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. **Lancet Oncol**. 2016 Apr 5. [Epub ahead of print]
141. Radaelli S, Stacchiotti S, Ruggieri P, Donati D, **Casali PG**, Palmerini E, Collini P, Gambarotti M, Porcu L, Boriani S, Gronchi A, Picci P. Sacral Chordoma: Long-Term Outcome of A Large Series of Patients Surgically Treated At Two Reference Centers. **Spine (Phila Pa 1976)**. 2016 Apr 6. [Epub ahead of print]
142. Raut CP, Miceli R, Strauss DC, Swallow CJ, Hohenberger P, van Coevorden F, Rutkowski P, Fiore M, Callegaro D, **Casali PG**, Haas RL, Hayes AJ, Honore C, Cannell AJ, Jakob J, Szacht M, Fairweather M, Pollock RE, Bonvalot S, Gronchi A. External validation of a multi-institutional retroperitoneal sarcoma nomogram. **Cancer**. 2016 May 1;122(9):1417-24. [Epub ahead of print]
143. Gronchi A, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, **Casali PG**, Pollock RE, Raut CP. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. **Ann Surg**. 2015 Dec 31. [Epub ahead of print]
144. Benjamin RS, **Casali PG**. Adjuvant Imatinib for GI Stromal Tumors: When and For How Long? **J Clin Oncol**. 2015 Dec 7. [Epub ahead of print]
145. Fiore M, Colombo C, Radaelli S, Callegaro D, Palassini E, Barisella M, Morosi C, Baldi GG, Stacchiotti S, **Casali PG**, Gronchi A. Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. **Eur J Cancer**. 2015 Dec;51(18):2800-7.
146. **Casali PG**, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WT, Zalcberg JR, Litière S, Blay JY. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. **J Clin Oncol**. 2015 Dec 20;33(36):4276-83.
147. Palassini E, Ferrari S, Verderio P, De Paoli A, Martin Broto J, Quagliuolo V, Comandone A, Sangalli C, Palmerini E, Lopez-Pousa A, De Sanctis R, Bottelli S, Libertini M, Picci P, **Casali PG**, Gronchi A. Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide. **J Clin Oncol**. 2015 Nov 1;33(31):3628-34.
148. Hindi N, **Casali PG**, Morosi C, Messina A, Palassini E, Pilotti S, Tamborini E, Radaelli S, Gronchi A, Stacchiotti S. Imatinib in advanced chordoma: A retrospective case series analysis. **Eur J Cancer**. 2015 Nov;51(17):2609-14.
149. Goldbraich E, Waks Z, Farkash A, Monti M, Torresani M, Bertulli R, **Casali PG**, Carmeli B. Understanding Deviations from Clinical Practice Guidelines in Adult Soft Tissue Sarcoma. **Stud Health Technol Inform**. 2015;216:280-4.

150. Stacchiotti S, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, Urbini M, Indio V, Maestro R, Gronchi A, Fiore M, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, **Casali PG**. Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP). **Clin Cancer Res**. 2015 Aug 10. [Epub ahead of print]
151. Barrios CH, Blackstein ME, Blay JY, **Casali PG**, Chacon M, Gu J, Kang YK, Nishida T, Purkayastha D, Woodman RC, Reichardt P. The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours. **Eur J Cancer**. 2015 Nov;51(16):2423-33
152. Proserpio T, Ferrari A, Lo Vullo S, Massimino M, Clerici CA, Veneroni L, Bresciani C, **Casali PG**, Ferrari M, Bossi P, Galmozzi G, Pierantozzi A, Licitra L, Marcegaglia S, Mariani L. Hope in cancer patients: the relational domain as a crucial factor. **Tumori**. 2015 Jul-Aug;101(4):447-54.
153. Callegaro D, Miceli R, Brunelli C, Colombo C, Sanfilippo R, Radaelli S, **Casali PG**, Caraceni A, Gronchi A, Fiore M. Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. **Br J Surg**. 2015 Aug;102(9):1079-87.
154. **Casali PG**. Adjuvant chemotherapy for soft tissue sarcoma. **Am Soc Clin Oncol Educ Book**. 2015;35:e629-33.
155. Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, Marzotto A, Boscato E, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Mariani L, Amore P, Gronchi A, **Casali PG**, Maestro R, Dei Tos AP. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naïve localized GIST: a population-based study. **Am J Surg Pathol**. 2015 Jul;39(7):922-30
156. Sandrucci S, Gatta G, Trama A, Dei Tos AP, **Casali PG**. Specialized teams or specialist networks for rare cancers? **Eur J Surg Oncol**. 2015 Sep;41(9):1115-7.
157. Tazzari M, Palassini E, Vergani B, Villa A, Rini F, Negri T, Colombo C, Crippa F, Morosi C, **Casali PG**, Pilotti S, Stacchiotti S, Rivoltini L, Castelli C. Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. **BMC Cancer**. 2015;15:58.
158. Dittrich C, Negrouk A, **Casali PG**; European Society for Medical Oncology (ESMO) Switzerland, and the European Organisation for Research and Treatment of Cancer (EORTC), Belgium. An ESMO-EORTC position paper on the EU Clinical Trials Regulation and EMA's Transparency Policy: Making European research more competitive again. **Ann Oncol**. 2015 May;26(5):829-32.
159. Lee CK, Goldstein D, Gibbs E, Joensuu H, Zalcberg J, Verweij J, **Casali PG**, Maki RG, Cioffi A, McArthur G, Lord SJ, Yip D, Kanjanapan Y, Rutkowski P. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. **Eur J Cancer**. 2015 May;51(7):852-60.
160. Provenzano S, Hindi N, Morosi C, Ghilardi M, Collini P, **Casali PG**, Stacchiotti S. Response of conventional chondrosarcoma to gemcitabine alone: a case report. **Clin Sarcoma Res**. 2015 Mar 15;5:9.
161. Sanfilippo R, Dileo P, Blay JY, Constantinidou A, Le Cesne A, Benson C, Vizzini L, Contu M, Baldi GG, Dei Tos AP, **Casali PG**. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. **Anticancer Drugs**. 2015 Jul;26(6):678-81.
162. Blay JY, **Casali PG**, Dei Tos AP, Le Cesne A, Reichardt P. Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future. **Oncology**. 2015;89(1):1-13
163. Stacchiotti S, Sommer J; **Chordoma Global Consensus Group**. Building a global consensus approach to chordoma: a position paper from the medical and patient community. **Lancet Oncol**. 2015 Feb;16(2):e71-83
164. Sanfilippo R, Bertulli R, Marrari A, Fumagalli E, Pilotti S, Morosi C, Messina A, Dei Tos AP, Gronchi A, **Casali PG**. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. **Clin Sarcoma Res**. 2014 Nov 22;4(1):16.
165. Gronchi A, Collini P, Miceli R, Valeri B, Renne SL, Dagrada G, Fiore M, Sanfilippo R, Barisella M, Colombo C, Morosi C, Stacchiotti S, **Casali PG**, Dei Tos AP, Pilotti S. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma. **Am J Surg Pathol**. 2015 Mar;39(3):383-93.
166. Colombo C, Miceli R, Le Péchoux C, Palassini E, Honoré C, Stacchiotti S, Mir O, **Casali PG**, Dômont J, Fiore M, Le Cesne A, Gronchi A, Bonvalot S. Sporadic extra abdominal wall desmoid-type fibromatosis: Surgical resection can be safely limited to a minority of patients. **Eur J Cancer**. 2015 Jan;51(2):186-92.
167. Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asafei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, Capozzi F, Biagini R, Gambarotti M, Fagioli F, **Casali PG**, Picci P, Ferrari S, Aglietta M; for the Italian Sarcoma Group. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. **Lancet Oncol**. 2015 Jan;16(1):98-107.
168. Palmerini E, Staals EL, Maki RG, Pengo S, Cioffi A, Gambarotti M, Picci P, Daolio PA, Parafioriti A, Morris C, Antonescu CR, Gronchi A, **Casali PG**, Donati DM, Ferrari S, Stacchiotti S. Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. **Eur J Cancer**. 2015 Jan;51(2):210-7.
169. Morosi C, Stacchiotti S, Marchianò A, Bianchi A, Radaelli S, Sanfilippo R, Colombo C, Richardson C, Collini P, Barisella M, **Casali PG**, Gronchi A, Fiore M. Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: Analysis of 291 consecutive patients at a tertiary reference sarcoma center. **Eur J Surg Oncol**. 2014 Dec;40(12):1662-70.

170. Gronchi A, Miceli R, Allard MA, Callegaro D, Le Péchoux C, Fiore M, Honoré C, Sanfilippo R, Coppola S, Stacchiotti S, Terrier P, **Casali** PG, Le Cesne A, Mariani L, Colombo C, Bonvalot S. Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection. **Ann Surg Oncol**. 2015 May;22(5):1447-54.
171. **Casali** PG, Bruzzi P, Bogaerts J, Blay JY; on behalf of the Rare Cancers Europe (RCE) Consensus Panel. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. **Ann Oncol**. 2015 Feb;26(2):300-306.
172. Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, **Casali** PG, Zaffaroni N. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. **Eur J Cancer**. 2014 Nov;50(17):3021-8.
173. Angelini S, Ravegnini G, Nannini M, Bermejo JL, Musti M, Pantaleo MA, Fumagalli E, Venturoli N, Palassini E, Consolini N, **Casali** PG, Biasco G, Hrelia P. Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. **Eur J Hum Genet**. 2014 Sep 17.
174. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2014 Sep;25 Suppl 3:iii21-6.
175. ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2014 Sep;25 Suppl 3:iii113-23.
176. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2014 Sep;25 Suppl 3:iii102-12.
177. De Cecco L, Negri T, Brich S, Mauro V, Bozzi F, Dagrada G, Disciglio V, Sanfilippo R, Gronchi A, D'Incalci M, **Casali** PG, Canevari S, Pierotti MA, Pilotti S. Identification of a gene expression driven progression pathway in myxoid liposarcoma. **Oncotarget**. 2014 Aug 15;5(15):5965-77.
178. Tazzari M, Negri T, Rini F, Vergani B, Huber V, Villa A, Dagrada P, Colombo C, Fiore M, Gronchi A, Stacchiotti S, **Casali** PG, Pilotti S, Rivoltini L, Castelli C. Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. **Br J Cancer**. 2014 Sep 23;111(7):1350-62.
179. Bellera CA, Penel N, Ouali M, Bonvalot S, **Casali** PG, Nielsen OS, Delannes M, Litière S, Bonnetain F, Dabakuyo TS, Benjamin RS, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grosclaude P, Gronchi A, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Krarup-Hansen A, Le Péchoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut C, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van Glabbeke M, Woll P, Gourgou-Bourgade S, Mathoulin-Pélissier S. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. **Ann Oncol**. 2014 Jul 28.
180. **Casali** PG; European Society for Medical Oncology (ESMO) Switzerland. Risks of the new EU Data Protection Regulation: an ESMO position paper endorsed by the European oncology community. **Ann Oncol**. 2014 Aug;25(8):1458-61.
181. Ciardiello F, Arnold D, **Casali** PG, Cervantes A, Douillard JY, Eggermont A, Eniu A, McGregor K, Peters S, Piccart M, Popescu R, Van Cutsem E, Zielinski C, Stahel R. Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). **Ann Oncol**. 2014 Sep;25(9):1673-8.
182. Milione M, Gasparini P, Sozzi G, Mazzaferro V, Ferrari A, **Casali** PG, Perrone F, Tamborini E, Pellegrinelli A, Gherardi G, Arrigoni G, Collini P, Testi A, De Paoli E, Aiello A, Pilotti S, Pelosi G. Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported EWSR1-FEV translocation. **Histopathology**. 2014 Jun;64(7):1014-26.
183. **Casali** PG. Successes and limitations of targeted cancer therapy in gastrointestinal stromal tumors. **Prog Tumor Res**. 2014;41:51-61.
184. Stacchiotti S, Pantaleo MA, Astolfi A, Dagrada GP, Negri T, Dei Tos AP, Indio V, Morosi C, Gronchi A, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestro R, Pilotti S, **Casali** PG. Activity of sunitinib in extraskeletal myxoid chondrosarcoma. **Eur J Cancer**. 2014 Jun;50(9):1657-64.
185. **Casali** PG. Rare cancers: work in progress in Europe. **Ann Oncol**. 2014 Apr;25(4):914.
186. Radaelli S, Stacchiotti S, **Casali** PG, Gronchi A. Emerging therapies for adult soft tissue sarcoma. **Expert Rev Anticancer Ther**. 2014 Jun;14(6):689-704.
187. Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczky M, Cats A, **Casali** PG, Treckmann J, van Coevorden F, Gronchi A. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - analysis of prognostic factors (EORTC-STBSG collaborative study). **Eur J Surg Oncol**. 2014 Apr;40(4):412-9.
188. Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, Le Cesne A, Gladdy RA, **Casali** PG, Swallow CJ, Gronchi A, Bonvalot S, Raut CP. Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. **Ann Surg**. 2014 May;259(5):973-8.

189. Stacchiotti S, Dagrada GP, Sanfilippo R, Negri T, Vittimberga I, Ferrari S, Grosso F, Apice G, Tricomi M, Colombo C, Gronchi A, Dei Tos AP, Pilotti S, **Casali PG**. Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. **Clin Sarcoma Res**. 2013 Dec 18;3(1):16.
190. Popescu RA, Schäfer R, Califano R, Eckert R, Coleman R, Douillard JY, Cervantes A, **Casali PG**, Sessa C, Van Cutsem E, de Vries E, Pavlidis N, Fumasoli K, Wörmann B, Samonigg H, Cascinu S, Cruz Hernández JJ, Howard AJ, Ciardiello F, Stahel RA, Piccart M. The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). **Ann Oncol**. 2014 Jan;25(1):9-15.
191. Gronchi A, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, **Casali PG**, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M, Bonvalot S; ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm - a position paper from the Italian and the French Sarcoma Group. **Ann Oncol**. 2014 Mar;25(3):578-83.
192. European Partnership Action Against Cancer consensus group, Borrás JM, Albrecht T, Audisio R, Briers E, **Casali P**, Esperou H, Grube B, Hamoir M, Henning G, Kelly J, Knox S, Nabal M, Pierotti M, Lombardo C, van Harten W, Poston G, Prades J, Sant M, Travado L, Valentini V, van de Velde C, van den Bogaert S, van den Bulcke M, van Hoof E, van den Neucker I, Wilson R. Policy statement on multidisciplinary cancer care. **Eur J Cancer**. 2014 Feb;50(3):475-80.
193. Gronchi A, De Paoli A, Dani C, Merlo DF, Quagliuolo V, Grignani G, Bertola G, Navarra P, Sangalli C, Buonadonna A, De Sanctis R, Sanfilippo R, Dei Tos AP, Stacchiotti S, Giorello L, Fiore M, Bruzzi P, **Casali PG**. Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. **Eur J Cancer**. 2014 Mar;50(4):784-92.
194. Di Giandomenico S, Frapolli R, Bello E, Uboldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro V, Tamborini E, Pilotti S, **Casali PG**, Grosso F, Sanfilippo R, Gronchi A, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JM, D'Incalci M. Mode of action of trabectedin in myxoid liposarcomas. **Oncogene**. 2014 Oct 30;33(44):5201-10.
195. Martin-Broto J, Gutierrez AM, Ramos RF, Lopez-Guerrero JA, Ferrari S, Stacchiotti S, Picci P, Calabuig S, Collini P, Gambarotti M, Bague S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martinez-Trufero J, Poveda A, **Casali PG**, Fernandez-Serra A, Lopez-Pousa A, Gronchi A. MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study. **Mol Cancer Ther**. 2014 Jan;13(1):249-59.
196. Stacchiotti S, Marrari A, Dei Tos AP, **Casali PG**. Targeted therapies in rare sarcomas: IMT, ASPS, SFT, PEComa, and CCS. **Hematol Oncol Clin North Am**. 2013 Oct;27(5):1049-61.
197. Stacchiotti S, Tortoreto M, Bozzi F, Tamborini E, Morosi C, Messina A, Libertini M, Palassini E, Cominetti D, Negri T, Gronchi A, Pilotti S, Zaffaroni N, **Casali PG**. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics. **Clin Cancer Res**. 2013 Sep 15;19(18):5192-201.
198. Gronchi A, **Casali PG**. Adjuvant therapy for high-risk soft tissue sarcoma in the adult. **Curr Treat Options Oncol**. 2013 Sep;14(3):415-24.
199. Rutkowski P, Gronchi A, Hohenberger P, Bonvalot S, Schöffski P, Bauer S, Fumagalli E, Nyckowski P, Nguyen BP, Kerst JM, Fiore M, Bylina E, Hoiczky M, Cats A, **Casali PG**, Le Cesne A, Treckmann J, Stoeckle E, de Wilt JH, Sleijfer S, Tielen R, van der Graaf W, Verhoef C, van Coevorden F. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. **Ann Surg Oncol**. 2013 Sep;20(9):2937-43.
200. Duranti L, Gronchi A, Stacchiotti S, Fiore M, **Casali PG**, Collini P, Pelosi G, Galeone C, Pastorino U. Localised thoracic sarcomas: outcome improvement over time at a single institution. **Eur J Cancer**. 2013 Aug;49(12):2689-97.
201. Sanfilippo R, Dei Tos AP, **Casali PG**. Myxoid liposarcoma and the mammalian target of rapamycin pathway. **Curr Opin Oncol**. 2013 Jul;25(4):379-83.
202. Stacchiotti S, Crippa F, Messina A, Pilotti S, Gronchi A, Blay JY, **Casali PG**. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. **Clin Sarcoma Res**. 2013 May 13;3(1):8.
203. Sanfilippo R, **Casali PG**. The intriguing patterns of tumor response to trabectedin. **Expert Rev Anticancer Ther**. 2013 Jun;13(6 Suppl 1):21-4.
204. Stacchiotti S, Libertini M, Negri T, Palassini E, Gronchi A, Fatigoni S, Poletti P, Vincenzi B, Dei Tos AP, Mariani L, Pilotti S, **Casali PG**. Response to chemotherapy of solitary fibrous tumour: a retrospective study. **Eur J Cancer**. 2013 Jul;49(10):2376-83.
205. Mattavelli D, Miceli R, Radaelli S, Mattavelli F, Cantù G, Barisella M, Quattrone P, Stacchiotti S, Sangalli C, **Casali PG**, Gronchi A, Fiore M. Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. **Ann Oncol**. 2013 Aug;24(8):2181-9.
206. Stacchiotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, Morosi C, Casale A, Crippa F, Conca E, Negri T, Palassini E, Marrari A, Palmerini E, Mariani L, Gronchi A, Pilotti S, **Casali PG**. Phase II study on lapatinib in advanced EGFR-positive chordoma. **Ann Oncol**. 2013 Jul;24(7):1931-6.

207. Baldi GG, Stacchiotti S, Mauro V, Dei Tos AP, Gronchi A, Pastorino U, Duranti L, Provenzano S, Marrari A, Libertini M, Pilotti S, **Casali** PG. Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. **Clin Sarcoma Res.** 2013 Apr 3;3:4.
208. **Casali** PG. Improving methodology to go beyond histology in rare cancers. **Lancet Oncol.** 2013 Apr;14(4):276-7.
209. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Ubaldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, **Casali** PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P. Role of macrophage targeting in the antitumor activity of trabectedin. **Cancer Cell.** 2013 Feb 11;23(2):249-62.
210. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, **Casali** PG; GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. **Lancet.** 2013 Jan 26;381(9863):295-302.
211. ESMO / European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol.** 2012 Oct;23 Suppl 7:vii92-9.
212. ESMO / European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol.** 2012 Oct;23 Suppl 7:vii49-55.
213. ESMO / European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol.** 2012 Oct;23 Suppl 7:vii100-9.
214. Angelini S, Pantaleo MA, Ravegnini G, Zenesini C, Cavrini G, Nannini M, Fumagalli E, Palassini E, Saponara M, Di Battista M, **Casali** PG, Hrelia P, Cantelli-Forti G, Biasco G. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. **Pharmacol Res.** 2013 Feb;68(1):1-6.
215. Gronchi A, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Palassini E, Stacchiotti S, Ferrari S, Fiore M, **Casali** PG. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. **Ann Oncol.** 2013 Mar;24(3):817-23.
216. Stiller CA, Trama A, Serraino D, Rossi S, Navarro C, Chirlaque MD, **Casali** PG; RARECARE Working Group. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. **Eur J Cancer.** 2013 Feb;49(3):684-95.
217. Stacchiotti S, Dagrada GP, Morosi C, Negri T, Romanini A, Pilotti S, Gronchi A, **Casali** PG. Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. **Clin Sarcoma Res.** 2012 Oct 11;2(1):22.
218. **Casali** PG. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. **Ann Oncol.** 2012 Sep;23 Suppl 10:x167-9.
219. Reichardt P, Blay JY, Boukovinas I, Brodowicz T, Broto JM, **Casali** PG, Decatris M, Eriksson M, Gelderblom H, Kosmidis P, Le Cesne A, Pousa AL, Schlemmer M, Verweij J, Joensuu H. Adjuvant therapy in primary GIST: state-of-the-art. **Ann Oncol.** 2012 Nov;23(11):2776-81.
220. Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, **Casali** PG, Balaña C, Schöffski P, Grosso F, Lardelli P, Nieto A, Alfaro V, Demetri GD. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. **Eur J Cancer.** 2012 Nov;48(16):3036-44.
221. **Casali** PG, Fumagalli E, Gronchi A. Adjuvant therapy of gastrointestinal stromal tumors (GIST). **Curr Treat Options Oncol.** 2012 Sep;13(3):277-84.
222. Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, Gronchi A, Dei Tos AP, Morosi C, Messina A, Pilotti S, **Casali** PG. Sunitinib malate in solitary fibrous tumor (SFT). **Ann Oncol.** 2012 Dec;23(12):3171-9.
223. Demetri GD, Garrett CR, Schöffski P, Shah MH, Verweij J, Leyvraz S, Hurwitz HI, Pousa AL, Le Cesne A, Goldstein D, Paz-Ares L, Blay JY, McArthur GA, Xu QC, Huang X, Harmon CS, Tassell V, Cohen DP, **Casali** PG. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. **Clin Cancer Res.** 2012 Jun 1;18(11):3170-9.
224. **Casali** PG, Dei Tos AP. A new journal... on spindle cells. **Clin Sarcoma Res.** 2011 Jul 25;1(1):1.
225. Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P, Llombart-Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, **Casali** PG, Gronchi A. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. **Cancer.** 2012 Dec 1;118(23):5857-66.
226. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, **Casali** PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. **Lancet.** 2012 May 19;379(9829):1879-86.
227. Colombo C, Miceli R, Collini P, Radaelli S, Palassini E, Stacchiotti S, Fiore M, Mariani L, **Casali** PG, Gronchi A. Leiomyosarcoma and sarcoma with myogenic differentiation: two different entities or 2 faces of the same disease? **Cancer.** 2012 Nov 1;118(21):5349-57.

228. Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, Spreafico C, Gronchi A, Amore P, Vinaccia V, **Casali** PG. Phase II study of imatinib in advanced chordoma. **J Clin Oncol**. 2012 Mar 20;30(9):914-20.
229. Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, **Casali** PG, Picci P. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. **J Clin Oncol**. 2012 Mar 10;30(8):850-6.
230. Negri T, Brich S, Conca E, Bozzi F, Orsenigo M, Stacchiotti S, Alberghini M, Mauro V, Gronchi A, Dusio GF, Pelosi G, Picci P, **Casali** PG, Pierotti MA, Pilotti S. Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma. **Genes Chromosomes Cancer**. 2012 Feb;51(2):111-26.
231. Trama A, Mallone S, Ferretti S, Meduri F, Capocaccia R, Gatta G, RITA working group. The burden of rare cancers in Italy: the surveillance of rare cancers in Italy (RITA) project. **Tumori**. Sep-Oct 2012;98(5):550-8.
232. Gatta G, van der Zwan JM, **Casali** PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R; RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. **Eur J Cancer**. 2011 Nov;47(17):2493-511.
233. Rossi S, Miceli R, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Toffolatti L, Laurino L, Mariani L, Vinaccia V, Gnocchi C, Gronchi A, **Casali** PG, Dei Tos AP. Natural history of imatinib-naïve GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. **Am J Surg Pathol**. 2011 Nov;35(11):1646-56.
234. **Casali** PG, Sanfilippo R. Uterine sarcomas: a multidisciplinary challenge. **Eur J Cancer**. 2011 Sep;47 Suppl 3:S326-7.
235. Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D'Incalci M, Dei Tos AP, Raspagliesi F, Judson I, **Casali** PG. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. **Gynecol Oncol**. 2011 Dec;123(3):553-6.
236. Fiore M, Colombo C, Locati P, Berselli M, Radaelli S, Morosi C, **Casali** PG, Gronchi A. Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava. **Ann Surg Oncol**. 2012 Feb;19(2):511-8.
237. Gronchi A, Miceli R, Colombo C, Stacchiotti S, Collini P, Mariani L, Sangalli C, Radaelli S, Sanfilippo R, Fiore M, **Casali** PG. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. **Ann Oncol**. 2012 Apr;23(4):1067-73.
238. **Casali** PG. Medical oncology: the long-awaited prize of recognition. **Ann Oncol**. 2011 Aug;22(8):1695-7.
239. Stacchiotti S, **Casali** PG. Systemic therapy options for unresectable and metastatic chordomas. **Curr Oncol Rep**. 2011 Aug;13(4):323-30.
240. Joensuu H, De Braud F, Grignani G, De Pas T, Spitalieri G, Coco P, Spreafico C, Boselli S, Toffalorio F, Bono P, Jalava T, Kappeler C, Aglietta M, Laurent D, **Casali** PG. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. **Br J Cancer**. 2011 May 24;104(11):1686-90.
241. Grignani G, Palmerini E, Dileo P, Asaferi SD, D'Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F, **Casali** PG, Ferrari S, Aglietta M. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. **Ann Oncol**. 2012 Feb;23(2):508-16.
242. Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, De Rosa P, Nuzzo A, Turano S, Morosi C, Dei Tos AP, Pilotti S, **Casali** PG. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. **Ann Oncol**. 2012 Feb;23(2):501-8.
243. Orsenigo M, Brich S, Riva C, Conca E, Bertulli R, Dileo P, Gronchi A, **Casali** PG, Pierotti MA, Tamborini E, Pilotti S. Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFRα and Bcl-2 expression in gastrointestinal stromal tumors. **Anal Quant Cytol Histol**. 2010 Aug;32(4):225-33.
244. Schöffski P, Taron M, Jimeno J, Grosso F, Sanfilippo R, **Casali** PG, Le Cesne A, Jones RL, Blay JY, Poveda A, Maki RG, Nieto A, Tercero JC, Rosell R. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. **Eur J Cancer**. 2011 May;47(7):1006-12.
245. Italiano A, Laurant A, Laroche A, **Casali** P, Sanfilippo R, Le Cesne A, Judson I, Blay JY, Ray-Coquard I, Bui B, Coindre JM, Nieto A, Tercero JC, Jimeno J, Robert J, Pourquier P. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. **Cancer**. 2011 Aug 1;117(15):3445-56.
246. Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, Conca E, Bozzi F, Cassinelli G, Gronchi A, **Casali** PG, Pilotti S. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. **Ann Oncol**. 2011 Jul;22(7):1682-90.
247. Gronchi A, Miceli R, Colombo C, Collini P, Stacchiotti S, Olmi P, Mariani L, Bertulli R, Fiore M, **Casali** PG. Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. **Ann Oncol**. 2011 Jul;22(7):1675-81.

248. Stacchiotti S, Pedeutour F, Negri T, Conca E, Marrari A, Palassini E, Collini P, Keslair F, Morosi C, Gronchi A, Pilotti S, **Casali** PG. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. **Int J Cancer**. 2011 Oct 1;129(7):1761-72.
249. Grignani G, Palmerini E, Stacchiotti S, Boglione A, Ferraresi V, Frustaci S, Comandone A, **Casali** PG, Ferrari S, Aglietta M. A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor- α or - β : An Italian Sarcoma Group study. **Cancer**. 2011 Feb 15;117(4):826-31.
250. Sanfilippo R, Miceli R, Grosso F, Fiore M, Puma E, Pennacchioli E, Barisella M, Sangalli C, Mariani L, **Casali** PG, Gronchi A. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. **Ann Surg Oncol**. 2011 Mar;18(3):720-5.
251. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Gallina G, Marzotto A, Sartor C, Barbareschi M, Cantaloni C, Messerini L, Bearzi I, Arrigoni G, Mazzoleni G, Fletcher JA, **Casali** PG, Talamini R, Maestro R, Dei Tos AP. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. **Am J Surg Pathol**. 2010 Oct;34(10):1480-91.
252. Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, Stacchiotti S, **Casali** PG, Gronchi A. Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. **Ann Surg Oncol**. 2010 Dec;17(12):3229-33.
253. **Casali** PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2010 May;21 Suppl 5:v98-102.
254. **Casali** PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2010 May;21 Suppl 5:v198-203.
255. **Casali** PG. Do rare cancers deserve specific strategies for cancer research? **Lancet Oncol**. 2010 Jun;11(6):506-7.
256. **Casali** PG, Sanfilippo R, D'Incalci M. Trabectedin therapy for sarcomas. **Curr Opin Oncol**. 2010 Jul;22(4):342-6.
257. Dileo P, Pricl S, Tamborini E, Negri T, Stacchiotti S, Gronchi A, Posocco P, Laurini E, Coco P, Fumagalli E, **Casali** PG, Pilotti S. Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study. **Int J Cancer**. 2011 Feb 15;128(4):983-90.
258. Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, Messina A, Pastorino U, Pierotti MA, **Casali** PG, Pilotti S. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. **Mol Cancer Ther**. 2010 May;9(5):1286-97.
259. Bonvalot S, Miceli R, Berselli M, Causeret S, Colombo C, Mariani L, Bouzaïene H, Le Péchoux C, **Casali** PG, Le Cesne A, Fiore M, Gronchi A. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. **Ann Surg Oncol**. 2010 Jun;17(6):1507-14.
260. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, **Casali** PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. **Cancer Res**. 2010 Mar 15;70(6):2235-44.
261. Ardoïno I, Miceli R, Berselli M, Mariani L, Biganzoli E, Fiore M, Collini P, Stacchiotti S, **Casali** PG, Gronchi A. Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. **Cancer**. 2010 May 15;116(10):2429-36.
262. Tamborini E, Virdis E, Negri T, Orsenigo M, Brich S, Conca E, Gronchi A, Stacchiotti S, Manenti G, **Casali** PG, Pierotti MA, Pilotti S. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. **Neuro Oncol**. 2010 Aug;12(8):776-89.
263. Gronchi A, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, Fiore M, **Casali** PG. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. **Ann Surg**. 2010 Mar;251(3):506-11.
264. Stacchiotti S, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, Gronchi A, **Casali** PG. Tumor response to sunitinib malate observed in clear-cell sarcoma. **Ann Oncol**. 2010 May;21(5):1130-1.
265. Stacchiotti S, **Casali** PG, Lo Vullo S, Mariani L, Palassini E, Mercuri M, Alberghini M, Pilotti S, Zanella L, Gronchi A, Picci P. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. **Ann Surg Oncol**. 2010 Jan;17(1):211-9.
266. Demetri GD, **Casali** PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. **Clin Cancer Res**. 2009 Sep 15;15(18):5910-6.
267. Mertens F, Antonescu CR, Hohenberger P, Ladanyi M, Modena P, D'Incalci M, **Casali** PG, Aglietta M, Alvegård T. Translocation-related sarcomas. **Semin Oncol**. 2009 Aug;36(4):312-23.

268. Mussi C, Ronellenfitch U, Jakob J, Tamborini E, Reichardt P, **Casali** PG, Fiore M, Hohenberger P, Gronchi A. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? **Ann Oncol**. 2010 Feb;21(2):403-8.
269. Le Cesne A, Van Glabbeke M, Verweij J, **Casali** PG, Findlay M, Reichardt P, Issels R, Judson I, Schoffski P, Leyvraz S, Bui B, Hogendoorn PC, Sciort R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. **J Clin Oncol**. 2009 Aug 20;27(24):3969-74.
270. **Casali** PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. **Ann Oncol**. 2009 May;20 Suppl 4:64-7.
271. Paulussen M, Bielack S, Jürgens H, **Casali** PG; ESMO Guidelines Working Group. Ewing's sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. **Ann Oncol**. 2009 May;20 Suppl 4:140-2.
272. Bielack S, Carrle D, **Casali** PG; ESMO Guidelines Working Group. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. **Ann Oncol**. 2009 May;20 Suppl 4:137-9.
273. **Casali** PG, Jost L, Sleijfer S, Verweij J, Blay JY; ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. **Ann Oncol**. 2009 May;20 Suppl 4:132-6.
274. Stacchiotti S, Marrari A, Tamborini E, Palassini E, Viridis E, Messina A, Crippa F, Morosi C, Gronchi A, Pilotti S, **Casali** PG. Response to imatinib plus sirolimus in advanced chordoma. **Ann Oncol**. 2009 Nov;20(11):1886-94.
275. Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Péchoux C, **Casali** PG, Le Cesne A, Gronchi A, Bonvalot S. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. **Ann Surg Oncol**. 2009 Sep;16(9):2587-93.
276. Grosso F, Sanfilippo R, Viridis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Pilotti S, **Casali** PG. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. **Ann Oncol**. 2009 Aug;20(8):1439-44.
277. Gronchi A, Judson I, Nishida T, Poveda A, Martin J, Reichardt P, **Casali** PG, Cesne AL, Hohenberger P, Blay JY. Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). **Eur J Cancer**. 2009 May;45(7):1103-6.
278. George S, Blay JY, **Casali** PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. **Eur J Cancer**. 2009 Jul;45(11):1959-68.
279. Gronchi A, Bonvalot S, Le Cesne A, **Casali** PG. Resection of uninvolved adjacent organs can be part of surgery for retroperitoneal soft tissue sarcoma. **J Clin Oncol**. 2009 Apr 20;27(12):2106-7; author reply 2107-8.
280. Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, Piovesan C, Dileo P, Torri V, Gronchi A, **Casali** PG. High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. **Radiology**. 2009 May;251(2):447-56.
281. Forni C, Minuzzo M, Viridis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, **Casali** P, D'Incalci M, Pilotti S, Mantovani R. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. **Mol Cancer Ther**. 2009 Feb;8(2):449-57.
282. Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A, Pierotti MA, **Casali** PG, Pilotti S. Response to sunitinib malate in advanced alveolar soft part sarcoma. **Clin Cancer Res**. 2009 Feb 1;15(3):1096-104.
283. Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, **Casali** PG, Gronchi A. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). **Eur J Surg Oncol**. 2009 Jul;35(7):739-45.
284. Gronchi A, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, Lozza L, Pennacchioli E, Mariani L, **Casali** PG. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. **J Clin Oncol**. 2009 Jan 1;27(1):24-30.
285. Miselli F, Negri T, Gronchi A, Losa M, Conca E, Brich S, Fumagalli E, Fiore M, **Casali** PG, Pierotti MA, Tamborini E, Pilotti S. Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors? **Transl Oncol**. 2008 Dec;1(4):177-86.
286. Mussi C, Collini P, Miceli R, Barisella M, Mariani L, Fiore M, **Casali** PG, Gronchi A. The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution. **Cancer**. 2008 Oct 1;113(7):1657-65.
287. **Casali** PG, Jost L, Sleijfer S, Verweij J, Blay JY; ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. **Ann Oncol**. 2008 May;19 Suppl 2:ii89-93.

288. **Casali** PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. **Ann Oncol**. 2008 May;19 Suppl 2:ii35-8.
289. **Casali** PG; Executive Committee of ESMO. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). **Ann Oncol**. 2007 Dec;18(12):1923-5.
290. Gronchi A, Olmi P, **Casali** PG. Combined modalities approach for localized adult extremity soft-tissue sarcoma. **Expert Rev Anticancer Ther**. 2007 Aug;7(8):1135-44.
291. Baratti D, Pennacchioli E, **Casali** PG, Bertulli R, Lozza L, Olmi P, Collini P, Radaelli S, Fiore M, Gronchi A. Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. **Ann Surg Oncol**. 2007 Dec;14(12):3542-51.
292. Joensuu H, De Braud F, Coco P, De Pas T, Putzu C, Spreafico C, Bono P, Bosselli S, Jalava T, Laurent D, **Casali** PG. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. **Ann Oncol**. 2008 Jan;19(1):173-7.
293. Mannavola D, Coco P, Vannucchi G, Bertulli R, Carletto M, **Casali** PG, Beck-Peccoz P, Fugazzola L. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. **J Clin Endocrinol Metab**. 2007 Sep;92(9):3531-4.
294. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, **Casali** PG. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. **Lancet Oncol**. 2007 Jul;8(7):595-602.
295. **Casali** PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. **Curr Opin Oncol**. 2007 Jul;19(4):367-70.
296. Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, Collini P, Lozza L, Mariani L, **Casali** PG, Gronchi A. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. **Cancer**. 2007 Jun 15;109(12):2522-31.
297. Orlandi E, Zonca G, Pignoli E, Stucchi C, Borroni M, Collini P, Cantù G, **Casali** PG, Grosso F, Cerrotta A, Fallai C, Olmi P. Postoperative radiotherapy for synovial sarcoma of the head and neck during pregnancy: clinical and technical management and fetal dose estimates. **Tumori**. 2007 Jan-Feb;93(1):45-52.
298. Miselli FC, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, Fiore M, **Casali** PG, Bertulli R, Carbone A, Pierotti MA, Tamborini E, Pilotti S. c-Kit/PDGFR gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. **Clin Cancer Res**. 2007 Apr 15;13(8):2369-77.
299. Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S, **Casali** PG. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. **Ann Surg**. 2007 Mar;245(3):341-6.
300. Verweij J, **Casali** PG, Kotasek D, Le Cesne A, Reichardt P, Judson IR, Issels R, van Oosterom AT, Van Glabbeke M, Blay JY. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISC-AGITG study 62005. **Eur J Cancer**. 2007 Apr;43(6):974-8.
301. Gronchi A, Miceli R, Fiore M, Collini P, Lozza L, Grosso F, Mariani L, **Casali** PG. Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. **Ann Surg Oncol**. 2007 May;14(5):1583-90.
302. Negri T, Casieri P, Miselli F, Orsenigo M, Piacenza C, Stacchiotti S, Bidoli P, **Casali** PG, Pierotti MA, Tamborini E, Pilotti S. Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient. **Br J Cancer**. 2007 Jan 15;96(1):180-1.
303. Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, Gronchi A, Perrone F, Carbone A, Pierotti MA, **Casali** PG, Pilotti S. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. **Clin Cancer Res**. 2006 Dec 1;12(23):6920-8.
304. Pennacchioli E, Deraco M, Mariani L, Fiore M, Mussi C, Collini P, Olmi P, **Casali** PG, Santinami M, Gronchi A. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. **Ann Surg Oncol**. 2007 Feb;14(2):553-9.
305. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, **Casali** PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. **Lancet**. 2006 Oct 14;368(9544):1329-38.
306. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, **Casali** PG, Pilotti S, Gronchi A. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. **Cancer**. 2006 Sep 1;107(5):1065-74.
307. Van Glabbeke M, Verweij J, **Casali** PG, Simes J, Le Cesne A, Reichardt P, Issels R, Judson IR, van Oosterom AT, Blay JY. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISC-AGITG). **Eur J Cancer**. 2006 Sep;42(14):2277-85.
308. Tamborini E, Pricl S, Negri T, Lagonigro MS, Miselli F, Greco A, Gronchi A, **Casali** PG, Ferrone M, Fermeglia M, Carbone A, Pierotti MA, Pilotti S. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. **Oncogene**. 2006 Oct 5;25(45):6140-6.

309. Grosso F, Dileo P, Sanfilippo R, Stacchiotti S, Bertulli R, Piovesan C, Jimeno J, D'Incalci M, Gescher A, **Casali PG**. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. **Eur J Cancer**. 2006 Jul;42(10):1484-90.
310. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, **Casali PG**, Zalcberg J, Verweij J, Van Glabbeke M, Hagemelijer A, Judson I; EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. **Eur J Cancer**. 2006 May;42(8):1093-103.
311. Lagonigro MS, Tamborini E, Negri T, Staurengo S, Dagrada GP, Miselli F, Gabanti E, Greco A, **Casali PG**, Carbone A, Pierotti MA, Pilotti S. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. **J Pathol**. 2006 Apr;208(5):615-23.
312. Fiore M, **Casali PG**, Miceli R, Mariani L, Bertulli R, Lozza L, Collini P, Olmi P, Mussi C, Gronchi A. Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity. **Ann Surg Oncol**. 2006 Jan;13(1):110-7.
313. Fiore M, Miceli R, Mussi C, Lo Vullo S, Mariani L, Lozza L, Collini P, Olmi P, **Casali PG**, Gronchi A. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. **J Clin Oncol**. 2005 Oct 20;23(30):7669-75.
314. Nonaka D, Kusamura S, Baratti D, **Casali P**, Cabras AD, Younan R, Rosai J, Deraco M. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. **Cancer**. 2005 Nov 15;104(10):2181-8.
315. Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ, Carnaghi C, **Casali P**, Porgiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. **Endocr Relat Cancer**. 2005 Sep;12(3):657-66.
316. Van Glabbeke M, Verweij J, **Casali PG**, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PC, Brown M, Bertulli R, Judson IR. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. **J Clin Oncol**. 2005 Aug 20;23(24):5795-804.
317. Zalcberg JR, Verweij J, **Casali PG**, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR; EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. **Eur J Cancer**. 2005 Aug;41(12):1751-7.
318. **Casali PG**, Picci P. Adjuvant chemotherapy for soft tissue sarcoma. **Curr Opin Oncol**. 2005 Jul;17(4):361-5.
319. Blay JY, Bonvalot S, **Casali P**, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A, McClure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD; GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. **Ann Oncol**. 2005 Apr;16(4):566-78. Erratum in: *Ann Oncol*. 2005 Jun;16(6):993.
320. Diment J, Tamborini E, **Casali P**, Gronchi A, Carney JA, Colecchia M. Carney triad: case report and molecular analysis of gastric tumor. **Hum Pathol**. 2005 Jan;36(1):112-6.
321. **Casali PG**, Bertulli R, Fumagalli E, Coco P, Grosso F, Stacchiotti S. Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors. **J Chemother**. 2004 Nov;16 Suppl 4:55-8.
322. Kusamura S, Raspagliesi F, Baratti D, Gronchi A, **Casali P**, Deraco M. Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: a feasibility study. **J Chemother**. 2004 Nov;16 Suppl 5:19-22.
323. Gronchi A, **Casali PG**, Mariani L, Miceli R, Fiore M, Lo Vullo S, Bertulli R, Collini P, Lozza L, Olmi P, Rosai J. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. **J Clin Oncol**. 2005 Jan 1;23(1):96-104.
324. Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M, **Casali PG**, Gronchi A. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. **Cancer**. 2005 Jan 15;103(2):402-8.
325. Verweij J, **Casali PG**, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. **Lancet**. 2004 Sep 25-Oct 1;364(9440):1127-34.
326. **Casali PG**, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico C, Bertieri R, Bertulli R, Colecchia M, Fumagalli E, Greco A, Grosso F, Olmi P, Pierotti MA, Pilotti S. Imatinib mesylate in chordoma. **Cancer**. 2004 Nov 1;101(9):2086-97.
327. Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, Bertulli R, Olmi P, **Casali PG**. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. **Cancer**. 2004 Aug 1;101(3):627-34.

328. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, **Casali PG**, Pierotti MA, Pilotti S. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. **Gastroenterology**. 2004 Jul;127(1):294-9.
329. Gronchi A, **Casali PG**, Fiore M, Mariani L, Lo Vullo S, Bertulli R, Colecchia M, Lozza L, Olmi P, Santinami M, Rosai J. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. **Cancer**. 2004 Jun 1;100(11):2448-55.
330. Tamborini E, Bonadiman L, Greco A, Gronchi A, Riva C, Bertulli R, **Casali PG**, Pierotti MA, Pilotti S. Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma. **Clin Cancer Res**. 2004 Feb 1;10(3):938-43.
331. Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, Navarra P, Collini P, Gronchi A, Olmi P, Fossati-Bellani F, **Casali PG**. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. **Cancer**. 2003 Aug 1;98(3):571-80.
332. Deraco M, **Casali P**, Inglese MG, Baratti D, Pennacchioli E, Bertulli R, Kusamura S. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. **J Surg Oncol**. 2003 Jul;83(3):147-53.
333. Gronchi A, **Casali PG**, Mariani L, Lo Vullo S, Colecchia M, Lozza L, Bertulli R, Fiore M, Olmi P, Santinami M, Rosai J. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. **J Clin Oncol**. 2003 Apr 1;21(7):1390-7.
334. de Pas T, **Casali PG**, Toma S, Romanini A, Massidda B, Comandone A, Labianca R, Massacesi C, Tucci A, Antimi M, Biasco G, Aglietta M, Apice G, de Braud F; Italian Sarcoma Group. Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas? **Oncology**. 2003;64(2):186-8.
335. Mezzelani A, Mariani L, Tamborini E, Agus V, Riva C, Lo Vullo S, Fabbri A, Stumbo M, Azzarelli A, **Casali PG**, Gronchi A, Sozzi G, Pierotti MA, Pilotti S. SYT-SSX fusion genes and prognosis in synovial sarcoma. **Br J Cancer**. 2001 Nov 16;85(10):1535-9.
336. Azzarelli A, Gronchi A, Bertulli R, Tesoro JD, Baratti D, Pennacchioli E, Dileo P, Rasponi A, Ferrari A, Pilotti S, **Casali PG**. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. **Cancer**. 2001 Sep 1;92(5):1259-64.
337. Collini P, Sampietro G, Bertulli R, **Casali PG**, Luksch R, Mezzelani A, Sozzi G, Pilotti S. Cytokeratin immunoreactivity in 41 cases of ES/PNET confirmed by molecular diagnostic studies. **Am J Surg Pathol**. 2001 Feb;25(2):273-4.
338. **Casali PG**, Licitra L, Bruzzi P. QUOROM and the search for an updated 'clinical method' in the era of evidence-based medicine. **Ann Oncol**. 2000 Aug;11(8):923-5.
339. Costantini M, Mencaglia E, Giulio PD, Cortesi E, Roila F, Ballatori E, Tamburini M, **Casali P**, Licitra L, Candis DD, Massidda B, Luzzani M, Campora E, Placido SD, Palmeri S, Angela PM, Baracco G, Gareri R, Martignetti A, Ragosa S, Zoda L, Ionta MT, Bulletti S, Pastore L. Cancer patients as 'experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO). **Qual Life Res**. 2000 Mar;9(2):151-9.
340. Mancuso T, Mezzelani A, Riva C, Fabbri A, Dal Bo L, Sampietro G, Perego P, **Casali P**, Zunino F, Sozzi G, Pierotti MA, Pilotti S. Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. **Lab Invest**. 2000 Jun;80(6):805-13.
341. Tamburini M, **Casali PG**, Miccinesi G. Outcome assessment in cancer management. **Surg Clin North Am**. 2000 Apr;80(2):471-86, viii.
342. Frustaci S, Buonadonna A, Romanini A, Comandone A, Dalla Palma M, Gamucci T, Verusio C, Lionetto R, Dani C, **Casali P**, Santoro A. Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian group on rare tumors. **Tumori**. 1999 Jul-Aug;85(4):229-33.
343. **Casali P**, Licitra L, Tondini C, de Braud F, Bruzzi P, Costa A, Cavalli F. START: a European state-of-the-art on-line instrument for clinical oncologists. **Ann Oncol**. 1999 Jul;10(7):769-73.
344. **Casali P**, Licitra L, Costantini M, Santoro A, Viterbori P, Bajetta E, Bruzzi P. Quality of life assessment and clinical decision-making. **Ann Oncol**. 1997 Dec;8(12):1207-11.
345. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, **Casali P**, Spooner D, Rankin E, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. **J Clin Oncol**. 1995 Jul;13(7):1537-45.
346. Buonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, **Casali P**, Demicheli R, Valagussa P. Drugs ten years later: epirubicin. **Ann Oncol**. 1993 May;4(5):359-69.
347. **Casali P**, Pastorino U, Azzarelli A, Bertulli R, Zucchinelli P, Devizzi L, Santoro A. Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. **Cancer Chemother Pharmacol**. 1993;31 Suppl 2:S228-32.
348. Azzarelli A, Quagliuolo V, **Casali P**, Fissi S, Montalto F, Santoro A. Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities. **Cancer Chemother Pharmacol**. 1993;31 Suppl 2:S210-2.
349. Azzarelli A, Quagliuolo V, Fissi S, **Casali P**, Garbuglia A, Bignami P, Santoro A, Andreola S, Gennari L. Intra-arterial induction chemotherapy for soft tissue sarcomas. **Ann Oncol**. 1992 Apr;3 Suppl 2:S67-70.

350. **Casali P**, Pastorino U, Zucchinelli P, Devizzi L, Azzarelli A, Quagliuolo V, Bignami P, Santoro A, Bonadonna G. Epirubicin plus ifosfamide and dacarbazine (EID) in advanced soft tissue sarcomas. **Ann Oncol.** 1992 Apr;3 Suppl 2:S125-6.
351. Bidoli P, Spinazzè S, Santoro A, **Casali P**, Bedini AV, Guzzon A. Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma. **Am J Clin Oncol.** 1990 Oct;13(5):424-6.
352. Pastorino U, Valente M, Santoro A, Gasparini M, Azzarelli A, **Casali P**, Tavecchio L, Rayasi G. Results of salvage surgery for metastatic sarcomas. **Ann Oncol.** 1990 Jul;1(4):269-73.
353. Gianni L, Viganò L, Surbone A, Ballinari D, **Casali P**, Tarella C, Collins JM, Bonadonna G. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. **J Natl Cancer Inst.** 1990 Mar 21;82(6):469-77.
354. Pastorino U, Valente M, Gasparini M, Azzarelli A, Santoro A, Tavecchio L, **Casali P**, Ravasi G. Median sternotomy and multiple lung resections for metastatic sarcomas. **Eur J Cardiothorac Surg.** 1990;4(9):477-81.

Capitoli di volumi a stampa, in inglese:

1. **Casali PG**, Dei Tos AP, Gronchi A. Gastrointestinal stromal tumor. In: *DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology* (DeVita VT, Lawrence TS, Rosenberg SA, eds), 12th edition, Philadelphia: Wolters Kluwer, 2023, pp. 604-617
2. **Casali PG**, Trama A (eds) – JARC (Joint Action on Rare Cancers). Rare Cancer Agenda 2030, 2019
3. **Casali PG**, Dei Tos AP, Gronchi A. Gastrointestinal stromal tumor. In: *DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology* (DeVita VT, Lawrence TS, Rosenberg SA, eds), 11th edition, Philadelphia: Wolters Kluwer, 2019, pp. 895-907
4. Gronchi A, Dei Tos AP, **Casali PG**. Sarcomas of soft tissues and bone. In: *Oxford Textbook of Oncology* (Kerr DJ, Haller DG, van de Velde CJH, Baumann M, eds), 3rd edition, Oxford: Oxford University Press, 2016, pp. 844-866
5. **Casali PG**, Dei Tos AP, Gronchi A. Gastrointestinal stromal tumor. In: *DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology* (DeVita VT, Lawrence TS, Rosenberg SA, eds), 10th edition, Philadelphia: Wolters Kluwer, 2014, pp. 745-756
6. **Casali PG**, Picci P. Sarcomas. In: *Textbook of Medical Oncology* (Cavalli F, Hansen HH, Kaye SB, eds.), 3rd Ed., London & New York: Taylor & Francis, 2004, pp. 235-248
7. Santoro A, **Casali P**. Sarcomas. In: *Textbook of Medical Oncology* (Cavalli F, Hansen HH, Kaye SB, eds.), 1st Ed., London: Dunitz, 1997, pp. 217-228
8. **Casali P**, Santoro A. Bone malignant tumours other than osteosarcoma and Ewing's sarcoma. In: Peckam M, Pinedo HM, Veronesi U. *Oxford Textbook of Oncology*, 1st Ed. Oxford: Oxford University Press, 1995, pp. 1976-1982
9. Santoro A, **Casali P**, Zucchinelli P. Ewing's sarcoma. In: Cvitkovic, Droz, Armand, Khoury. *Handbook of Chemotherapy in Clinical Oncology*. Scientific Communication International Ltd, 1993, pp. 680-682

Annex 2

List of Book chapters, in English

10. **Casali PG**, Dei Tos AP, Gronchi A. Gastrointestinal stromal tumor. In: *DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology* (DeVita VT, Lawrence TS, Rosenberg SA, eds), 12th edition, Philadelphia: Wolters Kluwer, 2023, pp. 604-617
11. **Casali PG**, Dei Tos AP, Gronchi A. Gastrointestinal stromal tumor. In: *DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology* (DeVita VT, Lawrence TS, Rosenberg SA, eds), 11th edition, Philadelphia: Wolters Kluwer, 2019, pp. 895-907
12. Gronchi A, Dei Tos AP, **Casali PG**. Sarcomas of soft tissues and bone. In: *Oxford Textbook of Oncology* (Kerr DJ, Haller DG, van de Velde CJH, Baumann M, eds), 3rd edition, Oxford: Oxford University Press, 2016, pp. 844-866
13. **Casali PG**, Dei Tos AP, Gronchi A. Gastrointestinal stromal tumor. In: *DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology* (DeVita VT, Lawrence TS, Rosenberg SA, eds), 10th edition, Philadelphia: Wolters Kluwer, 2014, pp. 745-756
14. **Casali PG**, Picci P. Sarcomas. In: *Textbook of Medical Oncology* (Cavalli F, Hansen HH, Kaye SB, eds.), 3rd Ed., London & New York: Taylor & Francis, 2004, pp. 235-248
15. Santoro A, **Casali P**. Sarcomas. In: *Textbook of Medical Oncology* (Cavalli F, Hansen HH, Kaye SB, eds.), 1st Ed., London: Dunitz, 1997, pp. 217-228
16. **Casali P**, Santoro A. Bone malignant tumours other than osteosarcoma and Ewing's sarcoma. In: Peckam M, Pinedo HM, Veronesi U. *Oxford Textbook of Oncology*, 1st Ed. Oxford: Oxford University Press, 1995, pp. 1976-1982
17. Santoro A, **Casali P**, Zucchinelli P. Ewing's sarcoma. In: Cvitkovic, Droz, Armand, Khoury. *Handbook of Chemotherapy in Clinical Oncology*. Scientific Communication International Ltd, 1993, pp. 680-682

Annex 3

List of **Books**

- **Casali PG**, Trama A (eds) – JARC (Joint Action on Rare Cancers). Rare Cancer Agenda 2030, 2019
- Bellani ML, Morasso G, Amadori D, Orrù W, Grassi L, **Casali PG**, Bruzzi P (a cura di). **Psiconcologia**. Milano, Masson; 2002
- **Casali P**, Licitra L, Santoro A. **Metodologia Clinica in Oncologia**. Napoli, Società Editrice Scientifica; 1991

I authorize the use of my personal data in compliance with the GDPR 679/16 and the Italian Legislative Decree 196/03.